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1 ABSTRACT (ENGLISH) 
 
The facts that low plasma concentrations of high density lipoprotein (HDL) is a risk 
factor for developing type 2 diabetes and that patients with type 2 diabetes have low 
plasma concentration of HDL provided the main rationales for the studies described 
in this thesis. The effects of HDL and low density lipoprotein (LDL) on the pancreatic 
islets are unclear, thus, the overall aims were to investigate whether HDL and LDL 
play a role in the regulation of pancreatic islet cell apoptosis, proliferation and 
secretory function. 
In the present study, HDL has been identified to play an important role on islet cell 
survival by decreasing basal islet cells apoptosis. Moreover, HDL protected human 
and mouse islet cells from IL-1 and glucose induced apoptosis, two factors that are 
increased in type 2 diabetes. Interestingly, the protective effect of HDL against IL-1 
induced -cell apoptosis was still observed when cells were treated with the 
delipidated protein moiety of HDL or with apolipoprotein A1 (ApoA1) the main protein 
component of HDL. Surprisingly, the protective effect of HDL against IL-1 induced -
cell apoptosis was also observed in the absence of the main HDL receptor, SRB1. 
Intracellularly, HDL decreased mRNA expression of Fas, a cell death receptor, and of 
inducible nitric oxide synthase (iNOS). Both factors are increased in the presence of 
IL-1 and are known to be involved in IL-1induced apoptosisMoreover, HDL 
increased FLIP expression, an inhibitory protein of the Fas signaling pathway. 
LDL decreased glucose-stimulated insulin secretion of -cells only in the presence of 
functional LDL receptor and without affecting insulin expression or production. Thus, 
cholesterol accumulation may play a crucial role in the defect in glucose-stimulated 
insulin secretion. Moreover, LDL decreased -cell proliferation, independently of 
functional LDL receptor expression. Liraglutide, a GLP-1 analogue, was able to 
counteract the anti-proliferative effects of LDL. 
The present work proposes that HDL plays a protective role on islet cells by 
decreasing basal apoptosis and protecting from glucose and IL-1 induced 
apoptosis. This work also suggests that plasma concentrations of LDL should be 
tightly regulated since prolonged exposure to LDL impairs insulin secretion and 
decreases islet cell proliferation, deleterious effects that were partially prevented by 
the GLP-1 analogue liraglutide. 
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2 ABSTRACT (GERMAN) 
 
Das Wissen, dass tiefe Plasmakonzentrationen von Lipoproteinen hoher Dichte (High 
density lipoproteins, HDL) ein Risikofaktor für die Entstehung von Diabetes Typ 2 
darstellen einerseits und dass andererseits Typ-2-Diabetes-Patienten tiefe HDL-
Konzentrationen in ihrem Plasma aufweisen, bildete die Grundlage zu den 
Experimenten, welche im Rahmen dieser Doktorarbeit durchgeführt wurden. Der 
Einfluss sowohl des HDLs wie auch des Lipoproteins geringer Dichte (Low density 
lipoprotein, LDL) auf die Langerhans’schen Inseln ist unklar. Folglich war das Ziel 
dieser Arbeit zu untersuchen, ob HDL und LDL eine Rolle spielen in der Regulation 
der Apoptose, Proliferation und Funktion der Langerhans’schen Inselzellen. 
In der vorliegenden Arbeit wurde HDL als wichtiger Akteur in der Erhaltung der 
Inselzellen identifiziert, indem es die basale Apoptoserate senkt. Darüber hinaus 
schützt HDL menschliche und Maus-Inselzellen vor Apoptose, die durch IL-1 und 
Glucose (beide Faktoren sind erhöht in Typ 2 Diabetes) induziert wird. Der 
schützende Effekt von HDL gegen die durch IL-1 induzierte Apoptose der -Zellen 
konnte reproduziert werden, wenn die Zellen anstelle von HDL entweder mit der 
delipidierten Protein-Fraktion von HDL oder mit Apolipoprotein A1 (ApoA1, dem 
Hauptbestandteil dieser Protein-Fraktion) behandelt wurden. Der protektive Effekt 
von HDL gegen die IL-1-induzierte Apoptose in -Zellen konnte auch in 
Abwesenheit von SRB1, dem Hauptrezeptor für HDL, nachgewiesen werden. 
Intrazellulär reduzierte HDL die mRNA-Expression sowohl von Fas, einem Rezeptor 
der Apoptose-Kaskade, als auch diejenige von iNOS (inducible nitric oxide synthase). 
Diese beiden Faktoren sind erhöht unter IL-1 und es ist bekannt, dass sie in die IL-
1-induzierte Apoptose involviert sind. Ausserdem erhöht HDL die Expression von 
FLIP, einem Protein, das hemmend auf den Fas-Signalweg wirkt. 
Im Gegensatz dazu verringert LDL die Glukose-Stimulierte Insulin Sekretion in den -
Zellen nur dann, wenn der LDL Rezeptor funktional vorhanden ist. Dabei wird weder 
die Insulinexpression noch -produktion durch LDL beeinträchtigt. Die Cholesterin-
Akkumulation wirkt sich folglich vor allem auf die Sekretion des Insulins nachteilig 
aus. Überdies vermindert LDL die Proliferation der -Zellen unabhängig von der 
Expression des LDL-Rezeptors. Nur Liraglutide, ein GLP-1-Analogon, konnte dem 
anti-proliferativen Effekt von LDL entgegenwirken. 
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Die vorliegende Arbeit stellt die These auf, dass HDL einen schützenden Einfluss auf 
Inselzellen durch die Verminderung der basalen Apoptose ausübt und ausserdem die 
Inselzellen vor der durch IL-1 induzierten Apoptose schützt. Diese Arbeit legt zudem 
nahe, dass die Plasma-LDL-Konzentration in engen Grenzen gehalten werden sollte, 
weil eine längere LDL-Exposition die Insulin-Sekretion beeinträchtigt und die 
Inselzellproliferation verringert. Diese schädliche Wirkung kann teilweise 
unterbunden werden durch Behandlung mit dem GLP-1-Analogon Liraglutide. 
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3 ABBREVIATIONS 
 
ABCA1: ATP-binding cassette transporter A1 
ACAT:  acyl-CoA:cholesterol acyltransferase 
acLDL: acetylated LDL 
ADP: adenosine diphosphate 
AMP: adenosine monophosphate 
ApoA1:  apolipoprotein A1 
ATP: adenosine triphosphate 
CETP:  cholesteryl ester transfer protein 
ECM: extracellular matrix 
ER:  endoplasmic reticulum 
ERK:  extracellular signal-regulated kinase 
FLIP:  FLICE inhibitory protein 
GIP: glucose-dependent insulinotropic polypeptide 
GLP-1:  glucagon like peptide 1 
HDL:  high density lipoprotein 
HMG-CoA: 3-hydroxyl-3-methyl-glutaryl-CoA 
IDL:  intermediate density lipoprotein 
IFN:  interferon 
IL-1:  interleukin-1 
iNOS:  inducible nitric oxide synthase 
JNK:    c-Jun NH2 terminal kinase 
KATP channel:  ATP-sensitive K+ channel 
LDL:  low density lipoprotein  
LDLR:  low density lipoprotein receptor 
lHDL:  lipid moiety of high density lipoprotein 
Lira:  liraglutide 
LXR:  liver X receptor 
MAPK:  mitogen-activated protein kinase 
NFB:  nuclear factor B 
NO:  nitric oxide 
oxLDL:  oxidized low density lipoprotein 
PCR:  polymerase chain reaction 
5 
pHDL:  protein moiety of high density lipoprotein 
PKB:  protein kinase B 
rHDL:  reconstituted high density lipoprotein 
S1P:  sphingosine-1-phosphate 
SOCS3:  suppressor of cytokine sigaling 3 
SRB1:  scavenger receptor B1 
SREBP-1c:  sterol regulatory element binding rotein 1c 
TNF:  tumor necrosis factor  
VLDL:  very low density lipoprotein 
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4 INTRODUCTION 
 
4.1 Diabetes 
 
4.1.1 The History of Diabetes 
Diabetes is an ancient disease and its symptoms, which include excessive drinking of 
water and frequent urination, were first reported by Egyptians 3500 years ago. Since 
then, many physicians have remarked on the sweet taste of diabetic’s urine. 
However, the cause of the sugar to show up in the urine of diabetics remained a 
mystery until 1889, when Joseph Von Mering and Oskar Minkowski conducted 
pancreatectomy in dogs and found out that the pancreas secretes a substance that 
affects the metabolism of sugar. In 1910, Sir Edward Albert Sharpey-Schafer 
suggested that people with diabetes were deficient in a single chemical that was 
normally produced by the pancreas. He proposed the name insulin for this 
substance, from the Latin insula (= island) and in reference to the insulin-producing 
islets of Langerhans in the pancreas [2]. In 1921, Frederick Grant Banting and 
Charles Herbert Best repeated the work of Von Mering and Minkowski, went further 
and could reverse diabetes induced in dogs by pancreatectomy by giving them an 
extract from the pancreatic islets of Langerhans of healthy dogs [3]. They went on to 
purify the hormone insulin from bovine pancreases thus resulting in an effective 
treatment, insulin injections. The first patient was treated in 1922. For this work, 
Banting and his laboratory director MacLeod received the Nobel Prize in Physiology 
or Medicine in 1923. The same year, the drug company Eli Lilly and Company was 
able to produce large quantities of highly refined, 'pure' insulin. Insulin was offered for 
sale shortly thereafter. 
 
4.1.2 Type 1 and type 2 diabetes 
The distinction between what is now known as type 1 diabetes and type 2 diabetes 
was first clearly made by Sir Harold Percival Himsworth, and published in January 
1936. He reasoned that diabetes could be caused not only by a lack of insulin but 
also by a lack of sensitivity to insulin [2]. 
Diabetes Mellitus is now defined as a group of metabolic disease characterized by 
high levels of blood glucose resulting from defects in insulin production, insulin action 
or both. The chronic hyperglycemia of diabetes is associated with long term damage, 
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dysfunction, and failure of various organs, especially the eyes, kidneys, nerves, 
heart, and blood vessels. The majority of cases of diabetes fall into two broad 
categories: type 1 and type 2  [4]. Type 1 diabetes, presents itself as complete or 
near complete deficiency of insulin secretion caused by an immune mediated 
selective destruction of the insulin producing -cells [5]. Type 1 diabetes accounts for 
5-10% of those with diabetes, and often occurs in childhood and adolescence, but 
can occur at any age. Autoimmune destruction of -cells has multiple genetic 
predispositions and is also related to environmental factors that are still poorly 
defined [6-8]. 
Type 2 diabetes accounts for 90-95% of those with diabetes. Most of the patients are 
obese and the disease can be described as a combination of resistance to insulin 
action and an inadequate compensatory insulin secretory response. Thus, the risk of 
developing type 2 of diabetes increases with age, obesity, and lack of physical 
activity. Type 2 diabetes is associated with a strong genetic predisposition. However, 
the genetics related to type 2 diabetes are complex and not clearly defined [4]. In 
2005, an estimated 1.1 million people died from diabetes, and almost half of diabetes 
deaths occur in people under the age of 70 years. Diabetes causes about 5% of all 
deaths globally each year. The World Health Organization (WHO) estimates that 
more than 180 million people worldwide have diabetes. This number is likely to more 
than double by 2030 (source: World Health Organisation). 
 
4.1.3 Pathogenesis of type 2 diabetes 
Type 2 diabetes appears to be a multifactorial disease. It is now commonly accepted 
that the disease arises when -cells fail to secrete sufficient amounts of insulin to 
meet the metabolic demand. An increased metabolic demand due to insulin 
resistance in several tissues usually precedes the development of hyperglycaemia. 
There is thus a period of normal or near-normal glycaemia in which pancreatic -cells 
compensate for insulin resistance by hyper secretion of insulin. However, this period 
of -cell compensation is followed by -cell failure, in which the pancreas fails to 
secrete sufficient amounts of insulin. The consequence of -cell failure, which is due 
to a loss of -cell function and mass [9-11], coupled with insulin resistance is the 
development of type 2 diabetes [12, 13]. Thus, in obese and lean diabetic patients, 
type 2 diabetes is marked by a decrease in -cell mass that can no longer 
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compensates for the increased metabolic load, due to especially obesity associated 
insulin resistance [14, 15]. Insulin resistance is a condition in which normal amounts 
of insulin are inadequate to produce a normal insulin response in fat, muscle and liver 
cells. Insulin resistance in adipocytes results in elevated hydrolysis of stored 
triglycerides leading to an increase in free fatty acids in the blood plasma. Insulin 
resistance in muscle cells reduces glucose uptake (and so local storage of glucose 
as glycogen), whereas insulin resistance in liver cells reduces storage of glycogen, 
making it unavailable for release into the blood when blood insulin levels fall 
(normally only when blood glucose levels are low), along with increased 
gluconeogenesis [16]. 
 
4.2 Regulation of pancreatic islet cell mass 
 
4.2.1 Pancreatic islet architecture and composition 
The islets of Langerhans, named from the German scientist who first observed and 
described them in 1869, are scattered throughout the pancreas and constitute about 
1-2% of the pancreas. An incompletely defined and variable capsule encloses the 
islet and partially separates endocrine cells from exocrine cells. Pancreatic islets are 
highly vascularised mini-organs. Classically, they contain four different cell types: 
insulin-producing -cells, glucagon-producing -cells, somatostatin-producing -cells, 
and pancreatic polypeptide-producing PP cells [17]. A fifth type of cells, grehlin-
producing epsilon-cells are present mainly during pancreas development and at birth 
but their number decline postnatally [18, 19]. Interspecies differences in islet 
architecture have been proposed. Some reports claim that normal adult murine islets 
have a -cell core and a non -cell mantle, whereas the human islet architecture 
does not have this core-mantle architecture and -cells and non -cells are 
intermingled. Nevertheless, most recent studies point to a similar sub-organisation of 
human islets, with multiple entities of sub-islets with a -cell core (Susanne Boner-
Weir & Gordon Weir, personal communication). Another possible species difference 
between human and rodent islets is the cell composition: the proportion of -cells in 
the human islets seems much less (55%) than in murine islets (77%), while the 
fraction of -cells appears greater in human islets (35%) than in murine islets (18%) 
[20-22]. 
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4.2.2 Insulin expression, biosynthesis and secretion 
The primary structure of insulin was determined by a British molecular biologist 
Frederick Sanger. It was the first protein to have its sequence determined and for this 
work, Sanger was awarded the Nobel Prize in Chemistry in 1958. In 1969, after 
decades of work, Dorothy Crowfoot Hodgkin determined the tertiary structure of the 
molecule by means of X-rays diffraction studies and was awarded the Nobel Prize in 
Chemistry in 1964 for the development of crystallography. 
The insulin gene is expressed exclusively in the -cells of the pancreatic islets. This 
hormone is released in the blood stream principally in response to elevated glucose 
levels but also to free fatty acids and amino acids. Glucose metabolism in the -cells 
generates intracellular signals which stimulate insulin secretion, insulin mRNA 
translation and insulin gene transcription. Insulin is synthesized in the -cell in the 
form of preproinsulin, which carries additional informations to target the nascent 
protein chain into the endoplasmatic reticulum (ER). There, after cleavage of the 
signal peptide, it folds efficiently to assume the native proinsulin structure stabilized 
by three disulphide bonds. Correctly folded proinsulin is directed to the Golgi 
apparatus from which it is efficiently sorted into secretory vesicles, where it is 
converted by proteolytic enzymes to insulin and C-peptide [23]. 
Glucose induces insulin secretion via a complex pathway. Following the uptake of 
glucose in the -cell by the glucose transporter glut2, glycolysis in the cell generates 
increasing amount of ATP. A rise in the cytosolic ATP/ADP ratio closes the KATP 
channel, thus depolarizing the -cell. This depolarization activates the voltage-gated 
Ca2+ channels and consequently elevates intracellular Ca2+. This promotes the 
insulin-containing granules translocation and binding to the cellular membrane, finally 
leading to insulin release [24, 25]. 
 
4.2.3 Regulation of pancreatic islet cell mass 
In healthy individuals, pancreatic -cell mass is maintained at an optimal level to 
maintain normal glycaemia. The adult -cells are plastic and able to increase their 
population to adapt to changes in metabolic demand, such as pregnancy and non 
diabetic obesity [26]. Net changes in -cell mass are reflective of the amount of 
growth and probably neogenesis minus the degree of death. In the circumstances of 
prolonged obesity and insulin resistance, the -cell works under pressure trying to 
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meet the increased metabolic demand, and eventually succumbs to a collective 
number of stresses that lead to an increase in -cell death, a subsequent reduction in 
-cell mass, and the eventual onset of type 2 diabetes [27]. The concept of 
insufficient -cell mass as the key factor in the pathogenesis of type 2 diabetes has 
only recently been widely acknowledged [10, 26]. Postnatal -cell growth is complex 
and contributed by several mechanisms, including replication, neogenesis and size 
[28]. -cell replication seems to be the primary means of increasing its population (for 
more details see next section) [29]. -cell neogenesis describes the formation of new 
-cells from the ductal epithelium of the pancreas. Although it is generally accepted 
that -cell neogenesis likely occurs, the mechanism is poorly defined [30, 31]. -cell 
volume also contributes to -cell mass, though it is unknown whether a bigger -cell 
means a larger capacity to produce, store and release insulin. 
 
4.2.4 Signals inducing and preventing -cell proliferation 
Both the ability to generate and expand large amounts of transplantable -cells and 
the capacity to encourage-cell proliferation in the patient represent potential cures 
for diabetes. Understanding the basic cell cycle machinery responsible for the 
replication of -cell is therefore an important challenge in diabetes research [32]. The 
signal starting with extracellular mitogens is translated into intracellular mediators, 
which affect the cell cycle machinery composed of both activators and inhibitors. 
Cyclin-dependent kinases (CDK) and cyclins are generally responsible for driving the 
cell cycle forward from G1 to S to G2 and finally to mitosis. Throughout this process, 
these activating factors are controlled by inhibitors (the CKI and INK families) [33] . 
The -cell’s decision to proliferate seems to reside with CDK4 and cyclin D2 [34]. The 
-cell mitogens include glucose, amino acids, insulin, GLP-1, low levels of IL-1 
gastrin, growth hormone, and IGF-1 and 2 among others [35-37]. The gluco-incretins 
hormones GIP and GLP-1 are secreted by intestinal endocrine cells and have been 
studied for many years because of their important effect to potentiate glucose-
stimulated insulin secretion. Moreover, both peptides have the potential to stimulate 
-cell proliferation and to protect the -cell from apoptosis [38]. The-cell replication 
rate is slow and the proliferation of human islet cells cultured in vitro is controversial 
[39]. 
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4.2.5 Signals inducing and preventing -cell death 
Pathways regulating -cell turnover are also implicated in -cell insulin secretory 
function, thus making -cell destruction and secretory defect indissociable in the 
development and progression of type 2 diabetes. 
Glucose is the key physiological regulator of insulin secretion. Short-term exposure of 
-cells to increasing glucose concentrations induces proliferation in a concentration-
dependent manner [40, 41]. However the proliferating capacities of these cells are 
suppressed following prolonged exposure to increased glucose concentration. One 
potential mechanism by which glucose regulates-cell mass could be explained by 
-cell production of IL-1 following glucose exposure, and subsequent Fas receptor 
up-regulation [42]. Interleukin-1 is a prototypic proinflammatory cytokine [43]. Upon 
activation of the Fas receptor by binding of Fas ligand, the activated receptor induces 
apoptosis of the activated cell [44]. In the presence of FLIP, a caspase-8 inhibitor, 
Fas engagement is directed to -cell proliferation. However excessive glucose 
stimulation can decrease FLIP and induce Fas receptor death signalling. 
IL-1 is a central cytokine regulating -cell function, viability and replication. At low 
concentrations IL-1 promotes -cell function and survival whereas at high 
concentrations it induces apoptosis. Moreover, IL-1 is found in increased amounts in 
the -cells of type 2 diabetic patients [42]. Sustained and intense IL-1 receptor 
engagement causes progressive functional impairment and is followed by cell death 
[45, 46]. IL-1 is cytotoxic to rodent -cells, causing inhibition of glucose-stimulated 
insulin secretion and expression of the gene Nos2 encoding inducible nitric oxide 
synthase (iNOS), which leads to nitric oxide (NO) formation and cell death [47]. The 
key signalling pathways activated by IL-1 in -cells are the mitogen-activated protein 
kinase (MAPK) and the nuclear factor kappa B (NFB) pathways. The MAPKs 
comprise ERK, p38 and JNK. Their activation is increased in -cells compared to non 
-cells, and this correlates with increased susceptibility to IL-1 toxicity [47]. NFB 
comprises a collection of dimers composed of various combinations of members of 
the Rel family. Five mammalian Rel proteins have been identified: p50, p52, c-Rel, 
p65 and RelB. Prior to cytokine exposure, NFB is sequestered in the cytoplasm by 
binding to inhibitor protein kappa B (IB). Following cytokine exposure, IB is 
phosphorylated, ubiquitinated and degraded by the proteasomal complex, liberating 
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NFB that is then able to translocate to the nucleus and bind B consensus 
sequences in promoter regions of numerous proinflammatory genes [48]. IL-1 
activates the transcription factor NFB in rodent and human islet cells, and blocking 
NFB activation prevents cytokine-induced apoptosis in these cells. The MAPK and 
NFB signalling pathways are not independent and interact together to induce 
cytokine response [47]. In rodent -cells, IL-1 induces the expression of iNOS 
resulting in production of NO. Both ERK and p38 are required for IL-1-induced iNOS 
expression and NO production. Moreover, NO contributes to cytokine-induced 
apoptosis via the activation and stimulation of JNK and p38 MAPK and suppression 
of Akt [49]. Cytokines, such as IL-1, either produced by the -cells themselves in 
response to hyperglycaemia or by inflammatory cells, which localize at the periphery 
of the islets, can participate in the induction of apoptosis [50, 51]. Adipokines, such 
as TNF, may also have deleterious effects on -cell survival. 
Due to the high secretory demand it endures, the endoplasmatic reticulum (ER) is 
very well developed and highly active in -cells. This also likely increases the 
susceptibility of these cells to ER stressors. However, activation of the unfolded 
protein response (UPR) in -cells in response to ER stress may also provide 
protection to -cells by attenuating the ability of cytokines such as IL-1 to signal and 
activate the expression of downstream targets [52-54]. The unfolded protein 
response (UPR) is a survival mechanism whereby malformed and misfolded proteins 
forming in the ER set off a response that leads to a down regulation of general 
protein synthesis. However, if the UPR is strong and extended chronically this can 
induce ER stress and apoptosis [52, 55]. 
Increased oxidative metabolism, due to increased metabolic demand, generates 
reactive oxygen species (ROS) and reactive nitrogen species (RNS) which ultimately 
activate stress-induced pathways, such as NFB or stress kinases, to influence cell 
fate [56, 57]. 
Each form of stress-induced apoptosis can be prevented or at least markedly 
reduced by GLP-1 treatment. Studies of the signaling pathways mediating the 
antiapoptotic actions of GLP-1 support a role for PI3K, Akt, cAMP, and MAPK in part 
via decreased level of caspase 3 and increased levels of Bcl-2 and Bcl-xl [58-60]. 
In obesity abnormal lipid deposition is found in many tissues other then adipose 
tissue, including -cells. Chronic accumulation of lipid in -cells causes -cell 
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dysfunction and apoptosis [61]. Long-term exposure of -cells to saturated fatty-acids 
such as palmitate appears highly toxic, whereas monounsaturated fatty acids such as 
oleate protect against both palmitate and glucose-induced -cell apoptosis [62, 63]. 
Finally, the combination of elevated blood glucose and lipid concentrations is 
particularly toxic for -cells [15].  
 
4.3 Lipoproteins 
 
4.3.1 Discovery of lipoproteins 
The first inkling that fat transport system existed in the blood of animals can be traced 
to Boyle in 1665. In 1774, Henon showed that this milky fluid contained fat, and in 
1924 Gage and Fish showed that blood taken from humans after a fatty meal 
contained tiny particles which they named chylomicrons. Cholesterol was first 
discovered in bile and gallstones by Poulletier de la Salle in 1769 and then 
rediscovered in 1815 by Chevreul who named it “cholesterine”. Only later was 
cholesterol found in blood (Boudet 1833). The high density lipoprotein (HDL) was first 
isolated from horse serum in 1929 by Marcheboeuf and the low density lipoprotein in 
1950 by Gofman. Later it was showed that flotation of plasma in the ultracentrifuge 
revealed an array of lipoproteins that included very low density lipoprotein (VLDL), 
low density lipoprotein (LDL) and HDL, and permitted quantitation. Free fatty acids 
were discovered in the plasma by Szent-Gyorgi and Tominaga in 1924 and 
reinvestigated by Dole, Gordon and Cherkes (1956). They explored the physiological 
significance of free fatty acids and their binding to albumin and found that they varied 
with feeding and fasting. From further studies, it was concluded that lipoprotein-
bound triglycerides were delivered to adipose cells for uptake after meals; during 
fasting, the fat cells secreted free fatty acids, which provided fuel for any tissue. The 
protein components of the lipoproteins were characterized in the period from 1960 to 
1970 and the LDL receptor was identified by Goldstein and Brown in 1974 [64]. 
 
4.3.2 Lipoproteins structure and metabolism 
A lipoprotein is a chemical assembly that contains both proteins and lipids. 
Cholesterol and triacylglycerol, which are water insoluble, are contained inside a core 
formed of phospholipids and proteins, thus rendering the molecule water soluble. The 
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lipid and protein composition varies between the different classes of lipoproteins. The 
lipoproteins are classified according to their density. Chylomicrons are the smaller 
and the less dense lipoproteins, followed by very low density lipoproteins (VLDL), low 
density lipoprotein (LDL) and finally by high density lipoproteins (HDL). The main role 
of lipoproteins is the transport of cholesterol in the circulation, which is an essential 
component of cell membranes and steroid hormones. 
Cholesterol is derived from both exogenous dietary sources and endogenous 
biosynthetic pathways. Dietary lipids are predominantly composed of triglycerides, 
phospholipids and cholesterol. They are taken up from the intestine by the 
enterocytes which esterifies and assembles them into chylomicrons. Endothelial-
bound lipoprotein lipase hydrolyses triglycerides in circulating chylomicrons to 
generate chylomicrons remnants. The glycerol and free fatty acids generated by the 
lipoprotein lipase action enter the muscle cells and adipocytes. The triglycerides 
depleted and thus cholesterol rich chylomicron remnants are taken up by 
hepatocytes, where they are degraded in the lysosomes. The cholesterol is then 
exported out of the liver in bile acids and finally excreted. Whereas during fasting, the 
cholesterol of the hepatocytes that originates from dietary lipids or from liver de novo 
synthesis is exported in the circulation by VLDL. These lipoprotein particles are of 
similar protein and lipid composition to chylomicrons but are smaller, synthesized in 
the liver and carry mainly endogenous lipids. Their function is to transport fatty acids 
to adipose tissue and muscle. In the circulation, as a result of the lipoprotein lipase 
(LPL) activity, VLDL are degraded in the same manner as chylomicrons are, thus 
releasing free fatty acids that are taken up by the muscle cells and the adipocytes. As 
a result of the large buoyant VLDL degradation, the particles shrink to become the 
smaller intermediary density lipoprotein (IDL) and then the even smaller LDL. Both 
the liver and the peripheral tissues can take up LDL. In humans, the majority of 
serum cholesterol is transported by LDL particles. The liver degrades about 40% to 
60% of LDL. The other major player in cholesterol metabolism is HDL. As LPL 
digests VLDL on the endothelial cell surface, some excess surface material 
(cholesterol and phospholipids) is transferred to the HDL, which transports excess 
cellular cholesterol back to the liver [1, 65] (fig 1+2). 
 
15 
 
 
 
 
 
 
 
4.4 High density lipoprotein and its receptors 
 
4.4.1 HDL structure and biosynthesis 
The HDL fraction in human plasma is heterogeneous in terms of size, shape, 
composition, and surface charge. The HDL particle can be discoidal or spherical. 
Figure 1: Pathways for cholesterol delivery and production. C indicates free cholesterol; CE, cholesteryl 
esters; TG, triglycerides; Rem, remnants; LPL, lipoprotein lipase; LDLR, LDL receptor [1]. 
Figure 2: Reverse cholesterol transport. C indicates free cholesterol; CE, cholesteryl esters; LCAT, 
lysolecithin cholesterol acyltransferase; CETP, cholesteryl ester transfer protein; LDLR, LDL receptor; 
SR-B1, scavenger receptor B1 [1]. 
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Discoidal HDL consists of a bilayer of phospholipids and a small amount of 
unesterified cholesterol. The hydrophobic phospholipids in the bilayer are surrounded 
by an annulus of apolipoproteins that renders the particle water-soluble. Most 
discoidal HDL contains two or three molecules of apolipoprotein-A1 (ApoA1). 
Spherical HDL contains a hydrophobic core of cholesteryl esters surrounded by a 
surface monolayer that consists of phospholipids, unesterified cholesterol and 
apolipoproteins. Lecithin cholesterol acyltransferase (LCAT) rapidly transforms 
discoidal HDL into spherical HDL [66]. Apolipoproteins are associated with HDL, 
mainly ApoA1 (70%) and ApoA2 (20%). Other proteins are also found associated 
with HDL and some of them have enzymatic activities: lecithin cholesterol acyl 
transferase (LCAT), cholesterol ester transfer protein (CETP), phospholipids transfer 
protein (PLTP) and paraoxanase [67]. 
HDL is synthesized through a complex pathway. HDL assembly initially involves the 
cell surface ATP-binding cassette transporter A1 (ABCA1) mediated transfer of 
cellular phospholipids and cholesterol to extracellular lipid-poor ApoA1. This is 
followed by the remodelling in the plasma of HDL particles by the esterification of 
cholesterol by the enzyme LCAT, the exchange between HDL and other lipoproteins 
of both apolipoproteins and lipids. Finally the hydrolysis of lipids of HDL is mediated 
by various lipases and exchange of lipids by the PLTP and CETP. The lipids will then 
be carried back to the liver by the LDL particles [68]. The liver is the major source of 
plasma HDL, and intestine is likely to be responsible for the remaining HDL 
biosynthesis [69]. 
 
4.4.2 HDL receptor and signal transduction 
The scavenger receptor family contains at least 9 members and was first discovered 
by Brown and Goldstein, who were developing an in vitro model for the deposition of 
LDL cholesterol in macrophages. They discovered that acetylation of LDL (acLDL) 
redirected the uptake of the particle from classic LDL receptor to a novel acLDL 
receptor. They also showed that these receptors mediated the binding of a 
remarkably wide variety of ligands [70]. Scavenger receptor class B type 1 (SRB1) 
was initially identified in a scavenger receptor expression cloning study using acLDL 
as the ligand [71].  SRB1 is a 509 amino acid long membrane glycoprotein with a 
molecular mass of 82 kDa. This protein contains a large extracellular domain and two 
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transmembrane domains with short cytoplasmic amino and carboxy-terminal 
domains. SRB1 binds a variety of ligands like acLDL, oxLDL, apoptotic cells, native 
LDL, VLDL and HDL. SRB1 binds HDL with high affinity, with larger spherical HDL 
binding more tightly than smaller HDL. Lipid-poor ApoA1 is a poor ligand for SRB1. 
SRB1 mediates both selective uptake of cholesteryl ester and other lipids from HDL 
and LDL and bidirectional unesterified cholesterol movement [68, 72]. SRB1 is 
expressed in a variety of tissues including liver, endothelial cells and ovaries. SRB1 
is expressed in mouse islets and TC3 cell, a mouse insulinoma cell line [73]. 
However, SRB1 is most highly expressed in tissues that are known to be dependent 
on HDL cholesterol for bile acid synthesis (liver) and steroidogenesis (adrenal gland, 
ovaries, and testis). SRB1 binds HDL and the core cholesteryl ester is delivered to 
the plasma membrane without concomitant uptake and degradation of the entire HDL 
particle. This process is termed the selective uptake pathway. In addition to this 
process, SRB1 also stimulates the bidirectional flux of free cholesterol between cells 
and lipoproteins. The function of the receptor in other tissue is unclear as well as its 
intracellular signal transduction [74]. In healthy endothelial cells, the SRB1 apoptotic 
pathway, which is caspase-8 mediated, is turned off by eNOS (endothelial nitric oxide 
synthase) and HDL, thus preventing inappropriate apoptotic damage to the vascular 
wall. When HDL levels are low, eNOS is relocalized away from SRB1, which turns on 
SRB1 induced apoptosis [75]. 
 
4.4.3 Biological actions of HDL 
HDL classically functions in reverse cholesterol transport, removing cholesterol from 
peripheral tissues and delivering it to the liver and to steroidogenic organs by binding 
of HDL to the high affinity HDL receptor SRB1. The risk of atherosclerosis, a 
progressive inflammatory disease characterized by the accumulation of lipids and 
fibrous elements within the wall of large arteries [76], is inversely related to circulating 
level of HDL cholesterol. In mouse models of atherosclerosis, ApoA1 and SRB1 
provide atheroprotection [77]. The protective nature of HDL has been previously 
attributed only to its role in reverse cholesterol transport. However, new studies show 
that alternative mechanisms of action of HDL must be considered. HDL inhibits the 
chemotaxis of monocytes, the adhesion of leukocytes to the endothelium, endothelial 
dysfunction, LDL oxidation, stimulates endothelial cell proliferation and inhibits 
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endothelial cell apoptosis. The latter effect seems to involve ApoA1 and sphingosine-
1-phosphate (S1P), the major bioactive lipid of HDL, and cellular protein synthesis 
but the precise mechanism remains largely unknown [78, 79]. TNF induced 
endothelial cell apoptosis is inhibited by HDL, and this is associated with attenuated 
induction of caspase-3 which is a component of all primary apoptotic pathways [80]. 
Growth factor deprivation related apoptosis of endothelial cells is also suppressed by 
HDL [81], and this involves the phosphorylation and activation of protein kinase B 
(PKB), known to be involved in cell survival [82]. All these recently discovered 
biological actions of HDL, as well as reverse cholesterol transport, remain to be 
further studied in order to understand the role of HDL in endothelial cell protection. 
And this may help to understand the role of HDL on other cell type, where studies are 
less abundant but could show that HDL affects their function and survival. 
 
4.4.4 ApoA1 structure and biosynthesis 
Plasma ApoA1 is a 243-residue protein synthesized primarily in the liver and the 
intestine [68]. In plasma, ApoA1 cycles between lipid-poor and lipid rich forms. The 
cycling was described in vitro and follows four different steps: (a) generation of 
monomolecular lipid-poor ApoA1 from spherical HDL; (b) acquisition by the lipid-poor 
ApoA1 of phospholipids and unesterified cholesterol from cell membranes and 
plasma lipoproteins to form discoidal HDL; (c) the conversion of discoidal HDL to 
spherical HDL; (d) the remodelling of the large spherical HDL by plasma factors in 
processes that result in the dissociation of monomolecular lipid-poor ApoA1. There 
are three potential sources of lipid-poor ApoA1 in the plasma: (a) it may be released 
as lipid-poor protein after its synthesis in the liver and intestine; (b) it may be 
generated in the plasma during remodelling of spherical HDL; (c) it may be released 
from triglyceride rich lipoproteins that are undergoing hydrolysis by lipoprotein lipase. 
Any lipid-poor ApoA1 that is generated in the plasma may either be excreted through 
the kidney and be irreversibly lost or it may be relipidated and retained in the plasma 
[66]. 
 
4.4.5 ATP-binding cassette transporter A1 
ATP-binding cassette transporter (ABC) is a superfamily of membrane transporters 
containing 48 members grouped into 7 subclasses labelled ABCA through ABCG. 
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Mutations in ABC genes cause a variety of diseases, including cystic fibrosis, 
Startgardt’s macular degeneration, and disturbances in lipid and lipoprotein 
metabolism. All ABC transporters use ATP to generate the energy needed to 
transport metabolites across the membranes. Four members of this large family have 
been shown to have a major impact on lipoprotein metabolism and cell cholesterol 
biology: ABCA1, ABCG1, ABCG5 and ABCG8.  
ABCA1 is a 2261 amino acid membrane protein. It is predicted to have a N terminus 
oriented in the cytosol and two large extracellular loops. ABCA1 mediates the 
transport of cholesterol, phospholipids and other lipophilic molecules across the 
cellular membranes, where they are removed from cells by lipid-poor HDL 
apoliproteins. It removes cholesterol that would otherwise accumulate as cytosolic 
cholesteryl ester droplets. The molecular mechanisms for ABCA1-mediated lipid 
efflux remains poorly understood. ABCA1 protein level and activity are highly 
regulated by multiple transcriptional and posttranscriptional processes. Excess 
intracellular cholesterol is converted to a “second messenger” oxysterol, which 
regulates ABCA1 through the activation of the nuclear receptor liver X (LXR). Under 
basal conditions, ABCA1 proteins are highly unstable. The interaction of apoliproteins 
with ABCA1 reduces the rate of the transporter degradation by inhibiting its 
proteolysis. Metabolites associated with inflammation and diabetes can destabilize 
ABCA1. Unsaturated fatty acids, which are elevated in diabetes and the metabolic 
syndrome, directly destabilize ABCA1 [1, 83, 84]. 
As nonhepatic cells are unable to degrade cholesterol, ABCA1 plays a critical role in 
regulating intracellular cholesterol metabolism [85]. Systemic ABCA1 knock-out mice 
have impaired glucose tolerance but normal insulin sensitivity. ABCA1 is highly 
expressed in islets -cells and absence of -cell ABCA1 results in accumulation of 
cellular cholesterol, reduction in insulin secretion and a progressive impairment in 
glucose tolerance. Thus, ABCA1 plays a critical role in -cell cholesterol homeostasis 
and is required for proper insulin secretion [86]. 
ABCA1 is mainly known as a transporter but it also acts as a full ApoA1 receptor that 
transduces signal from ApoA1 by complexing and activating cdc42, a small G protein, 
and downstream kinases [87]. 
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4.4.6 Biological actions of ApoA1 
ApoA1, as the major protein component of HDL, plays a critical role in reverse 
cholesterol transport by its interaction in its lipid-poor form with ABCA1. This induces 
lipid loading of the particle and thus deloading lipid from the cell. Increased plasma 
concentration of ApoA1 correlates inversely with the incidence of coronary arterial 
disease [88, 89]. This can be explained by an increase in HDL concentration which 
implicates an increased reverse cholesterol transport. However other mechanisms 
are possibly also responsible of the decrease of the incidence of coronary arterial 
disease. ApoA1 has been shown to protect endothelial cells from apoptosis by a yet 
unknown mechanism. Moreover, ApoA1 mimetic peptides reduce the inflammation 
markers induced by endotoxin in endothelial cells [90]. 
Type 2 diabetes patients have a reduced circulating HDL concentration which 
corresponds to a decrease in ApoA1 concentration, due to an elevated clearance of 
HDL molecule and simultaneously of ApoA1 [91, 92]. Glucose inhibits and insulin 
stimulates the expression of endogenous ApoA1 mRNA in human hepatic cells [93]. 
Thus, the reduced ApoA1 plasma concentration in type 2 diabetes seems to be a 
consequence of increased clearance of HDL and ApoA1 and decreased mRNA 
ApoA1 expression [94], due to elevated glucose concentration and reduced insulin 
concentrations or insulin sensitivity. ApoA1 positively modulates glucose 
homeostasis, by stimulating the phosphorylation of AMP kinase and acetyl-coenzyme 
A carboxylase and thus elevating glucose uptake in myocytes [95]. Through this 
mechanism, ApoA1 stimulates glucose utilisation and improves insulin resistance in 
peripheral tissues. In this regard, ApoA1 seems to be an important target for the 
prevention and therapy of type 2 diabetes. 
 
4.4.7 Sphingosine-1-phosphate structure and biosynthesis 
About 10 years ago, sphingosine-1-phosphate-like (S1P-like) lipids were shown for 
the first time to be associated with plasma lipoproteins [96]. One of these S1P-like 
lipids was then identified as being S1P. S1P concentration per unit amount of protein 
in lipoprotein fractions is mostly in HDL, then LDL and VLDL [97]. S1P is derived from 
shingosine, which was named in 1884 after the Greek mythological creature, the 
Sphinx, because of its enigmatic nature. Sphingolipids form a class of lipids 
characterized by a particular aliphatic aminoalcohol which is sphingosine. 
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Sphingosine can be released from ceramides, a process catalyzed by the enzyme 
ceramidase. S1P belongs to a class of lipid mediators that function not only inside the 
cell but also as ligands for specific cell surface receptors. S1P levels in cells are low 
and tightly regulated by the balance between its synthesis and degradation. The 
activity of the sphingosine kinase, which catalyses the ATP-dependent 
phosphorylation of sphingosine, is stimulated by many agonists indicating that it is a 
central regulating enzyme of S1P. The degradation of S1P is mediated by 2 different 
pathways: one is the reversible dephosphorylation back to sphingosine by S1P lyase 
and the second is the irreversible degradation by a S1P lyase [98]. 
 
4.4.8 Sphingosine-1-phosphate receptors and signal transduction 
To date five S1P receptors have been identified: S1P1, S1P2, S1P3, S1P4, S1P5. 
They are members of the superfamily of G protein coupled receptor (GPCR). S1P 
receptors consist of an extracellular N-terminal domain, 7 transmembrane domains 
and an intracellular C-terminal domain. S1P1, S1P2 and S1P3 are widely expressed in 
various tissues whereas the expression of S1P4 is confined to lymphoid and 
hematopoietic tissue and S1P5 to the central nervous system. All five receptors from 
this family bind to S1P with high affinity except for the S1P4 which binds preferentially 
phytosphingosine-1-phosphate. Binding of S1P to its receptors activates different 
signaling pathways via the heterotrimeric G proteins. S1P1 couples exclusively to Gi 
whereas S1P2 and S1P3 couples to Gi, Gq and G13, and S1P5 couples to Gi/o and G12. 
The coupling of the different receptors with different G proteins can activate many 
different downstream proteins, such as ERK, PLC, PI3K and Akt or inhibit the 
adenylate cyclase leading to a decrease in cAMP production. S1P receptors 
differentially regulate the small GTPase of the Rho family (Rho, Rac, cdc42) [98, 99]. 
 
4.4.9 Biological actions of sphingosine-1-phosphate 
S1P acts as an intracellular second messenger as well as an extracellular ligand for 
the S1P receptors. Diverse external stimuli, particularly growth and survival factors 
and chemoattractants, stimulate the S1P kinase to generate intracellular S1P. 
However, the targets of the intracellular S1P are not defined so far. S1P precursors, 
ceramide and sphingosine, have been associated with growth arrest and cell death 
[100, 101]. By contrast, S1P enhances growth and survival in different cell type [102]. 
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As these metabolites are interconvertible, it is probably not their absolute amounts, 
but rather their relative levels, that determine cell fate. Through the activation of 
different signaling pathways, S1P can regulate many different cellular functions, such 
as adherens junction assembly, cytoskeletal changes, migration, proliferation and 
apoptosis. S1P mediates the lipoprotein-induced cytoprotective actions through the 
S1P receptors and their intracellular signalling pathways [103]. 
Four S1P receptors (S1P1, S1P2, S1P3 and S1P4) are present on mouse and rat 
islets as well as on the rat insulinoma cell line INS-1 [104]. S1P acting on S1P 
receptors coupled to Gq mediates protective effects on islet -cells against cytokine-
induced apoptosis [105]. 
 
4.5 LDL and its receptors 
 
4.5.1 LDL structure and biosynthesis 
LDL is the major carrier of cholesterol in plasma. LDL has a highly-hydrophobic core 
consisting of esterified cholesterol. This core is surrounded by a shell of 
phospholipids and unesterified cholesterol as well as one single molecule of 
apoliprotein-B100 (ApoB100). ApoB100 is synthesized in the liver and intestine. LDL 
is formed from the lysis and digestion of VLDL in the circulation by LPL. LDL particles 
vary in size and density [65]. A higher concentration of small dense LDLs, which are 
more prone to modifications such as glycosylation and oxidation, is now recognized 
as a risk factor for developing cardiovascular diseases. As well, these small dense 
LDL particles are more present in patients suffering from type 2 diabetes [106]. 
 
4.5.2 LDL receptors and signal transduction 
LDL is recognized by a variety of receptors, depending also if the particle is under its 
native form or whether it is modified. They are members of either the LDL receptor 
family or the scavenger receptor family. The LDL receptor (LDLR), the founding 
member of the family, was the first to be discovered and has been extensively 
studied [107]. It is a membrane-spanning glycoprotein with a highly conserved 
structure in human and other species. The LDLR is synthesized in the rough 
endoplasmic reticulum as a precursor protein. Following the maturation process in 
the Golgi apparatus, the mature form of the receptor contains 839 amino-acid 
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residues with a molecular mass of 160 kDa, with 5 functional domains. The LDLR 
mediates the clearance of LDL particles from plasma. The mature LDL receptor 
proteins are guided to the cell surface, where they cluster into the coated pits on the 
cell membrane. Upon binding, the LDL-LDLR complex is taken up by the cells via 
clathrin-mediated endocytosis. In endosomes, the ligand dissociates from the 
receptor due to the local low pH. After dissociation, the LDLR recycles back to the 
cell surface. The LDL particle is targeted to the lysosomes where cholesterol is made 
available by hydrolysis of the cholesteryl esters. The free cholesterol released has 
the following effects: incorporation into membranes, inhibition of the synthesis of new 
LDLR, inhibition of cholesterol synthesis by reducing the synthesis of HMGCoA 
reductase and promotion of the activity of ACAT (acly CoA:cholesterol acyl 
transferase) which synthesizes cholesterol esters [108, 109]. These regulatory events 
are mediated by sterol regulatory element binding protein (SREBP) which monitors 
the free cholesterol concentration in the cell and adjusts the expression of the 
cholesterol regulatory genes [110]. LDLR transcription is controlled not only by 
cholesterol and its derivatives but also by cytokines, growth factors, hormones and 
secondary messengers. Insulin up regulates the transcription of LDLR [111, 112]. 
Mutations of LDLR gene underlie the lipid disorder familial hypercholesterolemia. 
The second member of the family cloned was the LDL receptor related protein 
(LRP1) [113]. LRP1 is a large endocytotic receptor widely expressed in several 
tissues and known to function in areas as diverse as lipoprotein transport, regulation 
of cell surface protease activity, and control of cellular entry of bacterial toxins and 
viruses [114-116] . Beside LRP1, apoER2 and VLDL receptor have been recognized 
as signal transducers, and binding of LDL. LDLR, LRP, VLDLR and apoER2 are 
expressed on mRNA and protein levels in mouse islets and the -cell line, TC3 [73]. 
 
4.5.3 Biological actions of LDL 
The major role of LDL is to deliver cholesterol to the tissues, especially to the liver 
and to steroidogenic cells. However, most of the LDL in circulation, around 70%, is 
taken up by the liver to be degraded. The liver either further degrades the cholesterol 
and extracts it from the body in the bile or recycles it and packs it for the circulation 
into VLDL. As mentioned above, LDL, especially when present in its small dense 
form, can be modified. Cholesterol accumulation in macrophages, as a consequence 
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of uncontrolled uptake of modified LDL particles by scavenger receptors (SR-A and 
CD36), leads to foam cells formation thereby contributing to the initiation and 
progression of atherosclerotic plaques. Modified LDL, and specifically oxidized LDL, 
has a detrimental effect on endothelial cells as well as on islet cells [117, 118]. 
Diabetic LDL triggers apoptosis in vascular endothelial cells [119]. 
 
4.6 Lipoproteins in diabetes 
 
Patients with type 2 diabetes have a dyslipidemia characterized by low plasma levels 
of HDL, increased level of serum triglycerides and free fatty acids. This so-called 
diabetic dyslipidemia is pro-atherogenic and can in part explain the marked increase 
in the risk of premature coronary heart disease in type 2 diabetes. In fact, the 
dyslipidemia might precede the manifestation of type 2 diabetes. This provides one 
explanation why many patients with type 2 diabetes have already manifested 
atherosclerothic diseases at the time point of diagnosis of diabetes [120-123]. 
The triglyceride level is related to an increased hepatic production of VLDL and a 
reduction of VLDL catabolism and a decreased HDL concentration due to an 
accelerate HDL catabolism. The VLDL overproduction seems to be mainly due to 
hepatic resistance to the inhibitory effect of insulin on VLDL production. Although 
plasma LDL level is usually normal in type 2 diabetic patients, LDL particles show 
kinetic abnormalities, such as reduced turn-over, which is potentially harmful. Type 2 
diabetic patients have an increased level of small dense LDL which are more prone 
to modifications such as oxidation or glycation [124]. Type 2 diabetes is associated 
with decreased plasma HDL, due to increased catabolism of HDL particles. 
Moreover, HDL particles in type 2 diabetes have qualitative abnormalities, such as 
enrichment in triglycerides and glycation of ApoA1 [124]. 
Finally, low HDL is a risk factor for developing type 2 diabetes [125] and subjects with 
predominance of small dense LDL have a greater than two-fold risk for developing 
type 2 diabetes [126]. 
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4.7 Role of lipoproteins and cholesterol in islets 
 
4.7.1 Cholesterol and islets 
Recent evidence suggests that alterations of plasma and islet cholesterol level may 
contribute to islet dysfunction and loss of insulin secretion. ABCA1, which regulates 
islet cholesterol efflux, is essential for normal -cell function, and absence of ABCA1 
results in islet cholesterol overload and impaired insulin release [86]. Cholesterol 
impairs -cell function and glucose-stimulated insulin secretion. Conversely, lowering 
-cell cholesterol levels with drugs increases insulin secretion [127]. Increasing islet 
cholesterol leads to reduced -cell function and in some studies increased -cell 
apoptosis [73, 127]. The most plausible hypothesis for cholesterol impaired insulin 
secretion is that, while cholesterol is critical for granule fusion, excess cholesterol 
causes dysregulation of raft formation and impairs exocytosis. Finally, several genetic 
alterations of cholesterol metabolism are associated with type 2 diabetes [128]. 
 
4.7.2 Lipoproteins and islets 
Functional lipoprotein receptors are present in mouse pancreatic islets and in TC3, 
a transformed-insulin secreting cell line. -cells express the LDL receptor, which is 
responsible for the uptake of LDL particles and their subsequent lysosomal 
degradation [73, 129]. Islets from LDL receptor -/- mice display markedly decreased 
LDL uptake compared with islets from wild type mice, thus concluding for a 
predominant role for LDL receptor in LDL uptake. However, in these LDL receptor -/- 
islets low levels of LDL uptake are still observed. This can be explained by the 
presence on the islets of ApoER2 [73], a receptor that can bind LDL with lower 
affinity [130]. SRB1 is also expressed on mouse islets and could explain the uptake 
of HDL particles by the islet cells. The role of VLDL and LDL in the apoptosis of islet 
cells is controversial. In one study, VLDL and LDL caused apoptosis in a time and 
concentration dependent manner [73]. A second study demonstrates that LDL 
causes death of islet -cells by its cellular uptake and subsequent oxidative 
modification. However, the cell death caused by LDL was claimed to be necrosis and 
not apoptosis. In the same study VLDL protects islet cells from the LDL induced 
death [131]. Only oxidised LDL and not native LDL causes apoptosis in islet cells in a 
third study, and this effect seems to be mediated by JNK [118]. LDL decreases 
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insulin gene expression only at high concentration, whereas oxLDL decreases it 
already with low concentration [73, 118]. In all studies investigating the role of 
lipoproteins on islet cells, HDL consistently affects islet cell survival and secretory 
function positively. In a study published by Roehrich and colleagues, HDL efficiently 
antagonized the proapoptotic effects of serum deprivation and incubation with 
cytokines (cocktail of IL-1 + TNF + IFN) or elevated LDL. This protective effect 
seems mediated by Akt, since incubation with HDL leads to increased Akt 
phosphorylation. Finally, Abderrahmani’s and colleagues describe that HDL 
counteracts the deleterious effect of oxLDL on islet cells [118].   
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4.8 Aim of the study 
 
Type 2 diabetes is characterized by a decrease in -cell mass that can no longer 
compensate for the metabolic load created by insulin resistance. Along with 
hyperglycaemia, patients with type 2 diabetes typically display elevated free fatty 
acids and triglyceride concentrations, and a decrease in HDL plasma concentration. 
Moreover, low HDL plasma concentration is a risk factor for developing type 2 
diabetes. Preliminary data in rodent -cell have indicated a role for lipoproteins in the 
regulation of cell survival. However, the precise role of HDL and LDL on human and 
mouse -cell survival, proliferation and secretory function remains to be investigated.  
The aim of my thesis is to determine the role of HDL and LDL on mouse and human 
-cell apoptosis, proliferation and secretory function, to investigate the putative 
protective role of HDL on islet cells in the context of type 2 diabetes, and to uncover 
the mechanisms of action of HDL and LDL in islet cells. Elucidating this may lead to 
knowledge on the mechanisms underlying the crucial role of lipoproteins in the 
development and progression of type 2 diabetes. 
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5 RESULTS 
 
5.1 Role of HDL on islet cells function, survival and apoptosis 
 
5.1.1 HDL and -cells function 
To examine the effect of HDL on mouse and human islet -cell function, islets were 
cultured for 4 days in the presence of various concentrations of HDL. Glucose-
stimulated insulin secretion in mouse and human -cells was not affected by the 
presence of HDL (fig 3A-C). 
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Figure 3: HDL and basal human and mouse -cell secretory function. Human and mouse islets were 
cultured for 4 days on extracellular matrix-coated dishes in the absence (control) or presence of HDL 
(human: 1 mM; mouse: 0.8mM). A: Glucose-stimulated insulin secretion in human -cells (n=5). B: 
Glucose-stimulated insulin secretion in mouse -cells (n=5). C: Glucose-stimulated insulin secretion in 
mouse -cells (n=5).  
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5.1.2 HDL and islet cells proliferation 
The role of HDL on basal human and mouse islet cells proliferation was evaluated by 
incubating human or mouse islets for 4 days with various concentrations of HDL. 
Proliferation of human and mouse islet cells was not influenced by the presence of 
HDL (fig 4A-C). 
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Figure 4: HDL and basal human and mouse islet cells proliferation. Human and mouse islets were 
cultured for 4 days on extracellular matrix-coated dishes in the absence (control) or presence of HDL 
(human: 1 mM; mouse: 0.8mM). A. Ki-67 positive human islet cells per islet (n=12), control (absolute 
value): 0.2 positive cells/islet. B: BrdU positive mouse islet cells per islet (n=5), control (absolute 
value) 5 positive cells/islet. C: BrdU positive mouse islet cells per islet (n=11), control (absolute value) 
3 positive cells/islet. 
 
 
5.1.3 HDL and islet cells apoptosis 
The role of HDL on basal human and mouse islet cells apoptosis was evaluated by 
incubating human or mouse islets for 4 days with various concentrations of HDL. 
Exposure of human islets to 1 mM HDL induced a 1.5 fold decrease in islet cells 
apoptosis (fig 5A). There was a tendency for HDL to decrease basal mouse islet cells 
apoptosis, in particular at 0.8 and 1.6 mM, however without reaching statistical 
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significance (fig 5B). Exposure to 0.8 mM HDL induced a 1.5 fold decrease in mouse 
islet cells apoptosis (fig. 5C), similarly to human islets. The basal rate of apoptosis 
after 2 days only tended towards a decrease in the presence of 0.8 mM HDL (fig 5D).  
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Figure 5: HDL decreases basal human and mouse islet cells apoptosis. Human and mouse islets were 
cultured in the absence (control) or the presence of HDL (human: 1 mM; mouse: 0.8 mM) for 2 (D) or 4 
(A, B, C) days on ECM-coated dishes. A: TUNEL positive human islet cells per islet (n=11), control 
(absolute value): 0.23 positive cells/islet. B: TUNEL positive mouse islet cells per islet (n=5) control 
(absolute value): 1.6 positive cells/islet. C and D: TUNEL positive mouse islet cells per islet after 4 
days (C, n=17) and 2 days (D, n=15), control (absolute value): 0.75 positive cells/islet (C), 0.52 
positive cells/islet (D). * represents p<0.05 by Student’s t test. 
 
 
5.1.4 HDL and islets in the presence of elevated glucose concentration 
Given the decrease in basal islet cells apoptosis by HDL, we hypothesized that HDL 
may protect human and mouse islet cells from the deleterious effects provoked by a 
prolonged exposure to elevated glucose concentration. Human and mouse islets 
were cultured for 4 days in the presence of elevated glucose concentration and 0.8 
mM (mouse) or 1 mM (human) HDL. 33 mM glucose induced a 2 fold increase in 
mouse and human islet cells apoptosis. Interestingly, HDL was able to reverse 
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apoptosis induced by the presence of elevated glucose concentrations in both 
species (fig 6A+B). When the glucose concentration was increased to 22 mM, the 
apoptosis induced was milder and thus the protective effect of HDL as well (fig 6C). 
After 4 days, glucose induced a 2 fold decrease in islet cells proliferation and this was 
not reversed by HDL, as shown in fig 7A for human islets and in fig 7C for mouse 
islets. In addition, HDL was unable to restore -cell glucose-stimulated insulin 
secretion impaired by a prolonged incubation with elevated glucose concentration (fig 
7B+D). 
 
 
 
  
Figure 6: HDL protects human and mouse islet cells from glucose induced apoptosis. Human islets 
were cultured for 4 days on ECM-coated dishes in 5 (control) or 33 mM glucose in the absence 
(control) or presence of HDL (1 mM). Mouse islets were cultured for 4 days on ECM coated dishes in 
11 (control), 22 or 33 mM glucose in the absence (control) or presence of HDL (0.8 mM). A: TUNEL 
positive human islet cells per islet (n=4), control: (absolute value) 0.11 positive cells/islet. B: TUNEL 
positive mouse islet cells per islet (n=7), control: (absolute value) 0.38 positive cells/islet. C: TUNEL 
positive mouse islet cells per islet (n=6), control: (absolute value) 0.62 positive cells/islet. Where * 
represents p<0.05 versus 33 mM as tested by ANOVA followed by Bonferroni’s post-hoc test. 
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Figure 7: HDL does not restore the impaired secretory function and the reduction in proliferation 
induced by elevated glucose. Human and mouse islets were cultured for 4 days on ECM-coated 
dishes in 5 (control human), 11 (control mouse) or 33 mM glucose in the absence (control) or 
presence of HDL (1 mM and 0.8 mM respectively). A: Ki-67 positive human islet cells per islet (n=2), 
control (absolute value): 0.46 positive cells/islet. B: Glucose-stimulated insulin secretion in human -
cells (n=3). C: BrdU positive mouse islet cells per islet (n=5), control (absolute value): 4.89 positive 
cells/islet. D: Glucose- stimulated insulin secretion in mouse -cells (n=3). Where * represents p<0.05 
tested by ANOVA followed by Bonferroni’s post-hoc test.  
 
 
5.1.5 HDL and islets in the presence of IL-1 
Since HDL appeared to protect islet cells from glucose-induced apoptosis, we 
hypothesized that HDL may also protect mouse islet cells from IL-1 induced 
apoptosis, since it has been proposed to mediate gluco-toxic effects. In order to test 
this hypothesis, mouse islets were incubated for 2 or 4 days with IL-1 in the 
presence or absence of HDL. Indeed, HDL protected mouse islet cells from IL-1 
induced apoptosis (fig 8A). The HDL protection of islet cells against IL-1 was not 
effective against impaired glucose-stimulated insulin secretion or decreased 
proliferation (fig 8B+C).  
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To determine which islet cell type HDL protected against IL-1 induced apoptosis, 
islets exposed for 2 days to IL-1 alone or with HDL were analysed for apoptosis by 
confocal microscopy. This method allowed us to identify apoptotic -cells (insulin 
positive) and non--cells (insulin negative). In fact, HDL protected mouse -cells from 
IL-1 induced apoptosis (fig 9A+B). 
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Figure 8: HDL protects mouse islets from IL-1 induced apoptosis. Mouse islets were cultured for 2 (A) 
or 4 days (B, C) on ECM coated-dishes in the absence (control) or presence of IL-1 (2 ng/ml) and in 
the absence (control) or presence of HDL (0.8 mM). A: TUNEL positive mouse islet cells per islet after 
2 days (n=16), control (absolute value): 0.46 positive cells/islet. B: BrdU positive mouse islet cells per 
islet after 4 days (n=3), control (absolute value): 3.36 positive cells/islet. C: Glucose-stimulated insulin 
secretion in mouse -cells after 4 days (n=3). Where * represents p<0.05 as tested by ANOVA 
followed by Bonferroni’s post-hoc test.  
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Figure 9: HDL protects mouse -cells from IL-1 induced apoptosis. Mouse islets were cultured for 2 
days on ECM-coated dishes in the absence (control) or presence of IL-1 (2 ng/ml) and in the 
absence (control) of presence of HDL (0.8 mM). A: TUNEL positive -cell per islet (n=4), control 
(absolute value): 0.32 positive cells/islet. B: Confocal microscope pictures of a representative islet co-
stained for insulin (1), TUNEL (2) and Dapi (3). Pictures of the different stainings and the overlay (4) 
are shown. Where * represents p<0.05 versus IL-1 as tested by ANOVA followed by Bonferroni’s 
post-hoc test.  
 
 
5.1.6 Receptor expression 
In order to evaluate the expression of the two receptors, SRB1 and ABCA1, a 
conventional PCR was performed on cDNA obtained from Min6 cells, mouse and 
human islets and on cDNA from purified human -cells with primers specific for these 
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receptors. ABCA1 and SRB1 transcripts could be detected in cDNA samples 
obtained from mouse islets (fig 10A). These 2 receptors are also present at the 
mRNA level in Min6 cells (fig 10B), and in human islets (fig 10C). In purified human 
-cells, ABCA1 and SRB1 also seem to be present at mRNA level. However, the 
weak signal observed with the PCR performed on RNA obtained from purified human 
-cells could also result from a contamination of the -cell fraction from the non -cell 
fraction (fig 10D). 
 
 
Figure 10: HDL receptor mRNA expression in human and mouse islet cells. Mouse islets, human 
islets, and purified human -cells were cultured for 4 days on ECM-coated dishes and RNA was 
extracted. Conventional PCR with specific primers was performed to detect the expression of the 
different receptors. A: Mouse islets. B: Min6 cells. C: Human islets. D: Purified human -cells. (+) and 
(-) represent cDNA and RT negative control respectively. (1): negative control; (2) total islet cells; (3): 
-cell fraction; (4): non--cell fraction 
 
 
5.1.7 Cell line 
Given the difficulties and variabilities of working with primary mouse and human 
islets, the murine cell lines Min6 and INS1 were tested in order to be used as working 
models for the protective effects of HDL. After 2 days incubation, HDL decreased 
basal apoptosis in Min6 cells and INS1 cells (fig 11A+12A), similarly to what was 
observed previously with mouse and human islet cells. However, HDL failed to 
protect Min6 and INS1 cells from IL-1 (fig 11B+12B) or glucose induced apoptosis 
(fig 12C). Due to the discrepancies between the results in primary cells and cell lines, 
only primary cells were used hereafter. 
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Figure 11: HDL does not protect Min6 cells from IL-1 induced apoptosis. Min6 cells were cultured for 
2 days in the absence (control) or presence of HDL (0.8 mM) and in the absence (control) or presence 
of IL-1 (2 ng/ml). A: Apoptosis in Min6 cells, relative to the absorbance (n=6). A: Apoptosis in Min6 
cells, relative to the absorbance (n=6). * represents p<0.05 by Student’s t test (A) or by ANOVA 
followed by Bonferonni’s post-hoc test (B).  
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Figure 12: HDL does not protect INS1 cells from IL-1 induced apoptosis. INS1 cells were cultured for 
2 days in the absence (control) or presence of HDL (0.8 mM) and in the absence (control) or presence 
of IL-1 (2 ng/ml) or glucose (33 mM). A: Apoptosis in INS1 cells, relative to the absorbance (n=8). B: 
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Apoptosis in INS1 cells, relative to the absorbance (n=8). C: Apoptosis in INS1 cells, relative to the 
absorbance (n=3). * represents p<0.05 by Student’s t test (A).  
 
 
5.1.8 HDL protein and lipid moieties and mouse islet cells apoptosis 
In order to identify which component of the HDL particle mediated the protective 
effect against IL-1 and glucose induced apoptosis, HDL was delipidated. Mouse 
islets were treated with either the delipidated protein moiety (pHDL) or the protein 
relipidated with phosphatidylcholine and cholesterol, which formed so called 
reconstituted HDL (rHDL), in the presence of elevated glucose concentration. 
Similarly to HDL, the HDL protein moiety, whether under its pure protein form or 
reconstituted with defined lipids, tended to decrease glucose induced apoptosis after 
4 days incubation (fig 13A+B). Since this protein moiety is composed of over 90% 
ApoA1, mouse islets were treated with purified ApoA1. Glucose and IL-1 induced 
apoptosis was decreased by ApoA1, however only the latter reached statistical 
significance (fig 13C+D). 
 
 
 
Figure 13: ApoA1 mediates the protective effect of HDL on islet cell apoptosis. Mouse islets were 
cultured for 2 (D) or 4 (A - C) days on ECM-coated dishes. A: TUNEL positive mouse islet cells per 
islet after 4 days culture in 11 (control) or 33 mM glucose in the absence (control) or presence of HDL 
protein moiety (pHDL 20 ug/ml) (n=3), control (absolute value): 0.35 positive cells/islet. B: TUNEL 
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positive mouse islet cells per islet after 4 days culture in 11 (control) or 33 mM glucose in the absence 
(control) or presence of reconstituted HDL (rHDL 20 ug/ml) (n=3), control (absolute value): 0.41 
positive cells/islet. C: TUNEL positive mouse islet cells per islet after 4 days culture in 11 (control) or 
33 mM glucose in the absence (control) or presence of ApoA1 (20 ug/ml) (n=3), control (absolute 
value): 0.17 positive cells/islet. D: TUNEL positive mouse islet cells per islet after 2 days culture in 11 
mM glucose in the absence (control) or presence of IL-1 (2 ng/ml) and in the absence (control) or 
presence of ApoA1 (20 ug/ml) (n=3), control (absolute value): 0.48 positive cells/islet. Where * 
represents p<0.05 as tested by ANOVA followed by Bonferonni’s post-hoc test.  
 
 
Surprisingly, the lipid moiety of HDL, obtained from HDL lipid extraction and 
consecutive reloading of the lipid extracted on bovine serum albumin (BSA), also 
protected islet cells from IL-1 induced apoptosis (fig 14A). IL-1 in the presence or 
absence of BSA induced islet cells apoptosis (data not shown). However, 
sphingosine-1-phosphate, a sphingolipid abundant in HDL lipid part that has been 
shown to exert a protective role on endothelial cells and proposed to mediate the 
effect of HDL [103], was unable to protect mouse islet cells from IL-1 induced 
apoptosis at low concentration (fig 14B). 
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Figure 14: At low concentration, sphingosine-1-phosphate does not protect islet cells from IL-
induced apoptosis. Mouse islets were cultured for 2 days on ECM-coated dishes. A: TUNEL positive 
mouse islet cells per islet after 2 days culture in 11 mM glucose in the absence (control) or presence 
of IL-1 (2 ng/ml) and in the absence (control) or presence of HDL lipid moiety (lHDL 0.8 mM) (n=4), 
control (absolute value): 0.61 positive cells/islet. B: TUNEL positive mouse islet cells per islet after 2 
days culture in 11 mM glucose in the absence (control) or presence of IL-1 (2 ng/ml) and in the 
absence (control) or presence of S1P (100 nM) loaded on BSA (n=4), control (absolute value): 0.43 
positive cells/islet. Where * represents p<0.05 as tested by ANOVA followed by Bonferonni’s post-hoc 
test. 
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5.1.9 Mechanisms of the protective effects of HDL 
Next, the underlying mechanisms of the anti-apoptotic effect of HDL were studied. 
Incubation of mouse islets with 0.8 mM HDL for 2 days strongly decreased basal 
iNOS mRNA expression (fig 15A). IL-1 induced iNOS mRNA expression in mouse 
islets, but not as much when HDL was present (fig 15B).  After 4 days incubation 
HDL modulated the expression of Fas and FLIP, two molecules involved in the 
extrinsic apoptotic pathway. Indeed, HDL induced a 1.5 fold down-regulation of the 
death receptor Fas whereas it causes a 1.5 fold up-regulation of FLIP, an inhibitory 
protein of the Fas pathway (fig 16A+B). The expression of SOCS3 and Bcl2 was not 
modulated by the presence of HDL (fig 16C+D). 
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Figure 15: HDL down regulates iNOS mRNA expression. Mouse islets were cultured for 2 days on 
ECM-coated dishes prior to RNA extraction. Semi-quantitative analysis of gene expression was 
performed with the Taq-Man technology. A: iNOS mRNA expression after 2 days incubation in the 
absence (control) or presence of HDL (0.8 mM) (n=5). B: iNOS mRNA expression after 2 days 
incubation in the absence (control) or presence of HDL (0.8 mM) and in the absence (control) or 
presence of IL-1 (2 ng/ml) (n=5). * represents p<0.05 by Student’s t test (A) or by ANOVA followed by 
Bonferonni’s post-hoc test (B). 
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Figure 16: HDL down regulates Fas und upregulates FLIP mRNA expression. Mouse islets were 
cultured for 4 days on ECM-coated dishes prior to RNA extraction. Semi-quantitative analysis of gene 
expression was performed with the Taq-Man technology. A: Fas mRNA expression after 4 days 
incubation in the absence (control) or presence of HDL (0.8 mM) (n=7). B: FLIP mRNA expression 
after 4 days incubation in the absence (control) or presence of HDL (0.8 mM) (n=6). C: Bcl2 mRNA 
expression after 4 days incubation in the absence (control) or presence of HDL (0.8 mM) (n=8). D: 
SOCS3 mRNA expression after 4 days incubation in the absence (control) or presence of HDL (0.8 
mM) (n=5). * represents p<0.05 by Student’s t test. 
 
 
Upstream of gene expression, IL-1 modulated phosphorylation of enzymes, and 
specifically MAP kinases. Incubation of mouse islets for 30 min with IL-1 increases 
the phosphorylation of JNK, ERK and p38, without influencing the amount of each 
protein (blot not shown). The increased phosphorylation of p38 induced by IL-1 is 
lower when HDL is added thereafter to the islets (fig 17). 
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Figure 17: HDL down regulates p38 phophsorylation. Mouse islets were incubated for 1 hour with HDL 
alone or 30 min with HDL alone and subsequently 30 min with HDL and IL-1β together. Proteins were 
extracted and phosphorylation of MAP kinases was analysed by western blot with specific antibodies. 
 
 
In an attempt to uncover which receptor is involved in the protection of -cells by HDL 
against IL-1 induced apoptosis, mouse islets obtained from SRB1 -/- animals were 
exposed for 2 days to IL-1 alone or in the presence of HDL. Islets obtained from wild 
type littermates were exposed to the same conditions and used as controls. The 
islets were analysed for apoptosis by confocal microscopy, allowing the identification 
of apoptotic -cells (insulin positive) and non--cells (insulin negative). HDL protected 
-cells from IL-1 induced apoptosis in wild type islets as well as in SRB1 -/- islets 
(fig 18A+B). However, IL-1 induced less apoptosis in SRB1 -/- -cells than in wild 
type -cells. This makes any conclusion on the role of SRB1 in the mediation of HDL 
effect difficult to interpret. 
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Figure 18: HDL protection of mouse -cells from IL-1 induced apoptosis is independant from SRB1. 
Mouse islets from wild type and SRB1 -/- were cultured for 2 days on ECM-coated dishes in the 
absence (control) or presence of IL-1 (2 ng/ml) and in the absence (control) of presence of HDL (0.8 
mM). A: TUNEL positive -cell per SRB1 -/- islet (n=3), control (absolute value): 0.48 positive 
cells/islet. B: TUNEL positive -cell per wild type islets (n=3), control (absolute value): 0.32 positive 
cells/islet. Where * represents p<0.05 as tested by ANOVA followed by Bonferonni’s post-hoc test  
 
 
5.2 Role of LDL on islet cells function, survival and apoptosis 
 
5.2.1 Receptor expression 
In order to evaluate the expression of the LDL receptor, a conventional PCR was 
performed on cDNA obtained from Min6 cells and human islets and on cDNA from 
purified human -cells with primers specific for these receptors. In agreement with 
previous studies LDL receptor transcripts could be detected in Min6 cells and human 
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islets (fig 19A-C). However, LDL receptor transcripts could not be detected in purified 
human -cells. 
 
Figure 19: LDL receptors mRNA expression in human and mouse islet cells. Min6 cells, human islets, 
and purified human -cells were cultured for 4 days on ECM-coated dishes and RNA was extracted. 
Conventional PCR with specific primers was performed to detect the expression of the LDL receptor. 
A: Min6 cells. B: Human islets. C: Purified human -cells. (+) and (-) represent cDNA and RT negative 
control respectively. (1): negative control; (2) total islet cells; (3): -cell fraction; (4): non--cell fraction 
 
 
5.2.2 LDL and islet cells function 
Since the LDL receptor is expressed in islet cells and was shown to be functional, the 
effects of LDL on islet function were investigated. Human and mouse islets were 
incubated for 4 days with LDL and glucose-stimulated insulin secretion was 
assessed. In both mouse and human islets, LDL decreased the stimulation of insulin 
secretion by glucose (fig 20A+B).  
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Figure 20: LDL decreases the glucose-stimulated insulin secretion in mouse and human -cells. 
Mouse and human islets were cultured for 4 days on ECM-coated dishes in the absence (control) or 
presence of LDL (3.1 mM). A: Glucose-stimulated insulin secretion in mouse -cells (n=5). B: Glucose-
stimulated insulin secretion in human -cells (n=6). * represents p<0.05 by Student’s t test. 
 
 
To investigate whether the LDL receptor was involved in the impairment of glucose-
stimulated insulin secretion induced by LDL, isolated mouse islets from LDL receptor 
-/- mice, as well as from wild type mice, were cultured for 4 days in the presence of 
LDL prior to the assessment of glucose-stimulated insulin secretion. The impairment 
of glucose-stimulated insulin secretion was observed in the wild type -cells, similar 
to what was obtained previously (fig 20A+21A), whereas this impairment was not 
observed with islets not expressing the LDL receptor (fig 21B). These data suggested 
that the impairment of glucose-stimulated insulin secretion due to LDL was 
dependent on functional LDL receptor. 
Given the impaired glucose-stimulated insulin secretion induced by LDL, we 
investigated whether LDL affected the production of insulin in islet cells. After 4 days 
incubation with LDL, islet insulin content and insulin mRNA were measured. LDL 
appeared to impair only the stimulation of insulin secretion since no difference was 
observed in insulin content and insulin gene expression in mouse islets from LDL 
receptor -/- and LDL receptor +/+ islets (fig 21C-F). 
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Figure 21: The LDL receptor mediates the functional impairment of islet cells induced by LDL. Mouse 
islets from LDR +/+ (A, C, E) and LDLR -/- (B, D, F) animals were cultured for 4 days on ECM-coated 
dishes in the absence (control) or presence of LDL (3.1 mM). A: Glucose-stimulated insulin secretion 
in LDLR +/+ mouse -cells (n=3). B: Glucose-stimulated insulin secretion in LDLR -/- mouse -cells 
(n=3). C: Total insulin content of LDLR +/+ islets (n=3). D: Total insulin content of LDLR-/- islets (n=3). 
E: Total insulin mRNA in LDLR+/+ islets (n=8). F: Total insulin mRNA in LDLR -/- islets (n=2). 
 
 
5.2.3 LDL and islet cells proliferation 
In order to investigate the role of LDL on islet cells proliferation, human and mouse 
islets were incubated in the presence of LDL for 2 and 4 days. After 4 days 
incubation, LDL decreased basal mouse and human islet cells proliferation up to 2 
A B 
C D 
E F 
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fold (fig 22B+D). This anti-proliferative effect could already be observed after 2 days 
in mouse islets (fig 22A). When LDL is incubated for 4 days in the presence of cells 
and glucose (5.5 mM for human and 11mM for mouse islets), the chances of LDL to 
be modified are elevated. In order to avoid a large increase in LDL modification, 
media and LDL were added freshly every day for 4 days. After 4 days, LDL 
decreased proliferation of islet cells (fig 22C). However, liraglutide, a GLP-1 analogue 
known to increase islet cells proliferation, was able to counteract the anti-proliferative 
effects of LDL on mouse islet cells (fig 23A). When LDL and media were changed 
every day during the incubation time (fig 23B) the same effects were observed. Thus, 
the anti-proliferative effects were strong enough not only to affect the basal but also 
the liraglutide induced islet cells proliferation. To determine which islet cell type is 
affected by LDL, single cells from isolated mouse islets were cultured for 4 days in 
the presence of LDL allowing us to distinguish between proliferative -cells and 
proliferative non--cells. Indeed, LDL decreased specifically -cell proliferation (fig 
24). 
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Figure 22: LDL decreases basal mouse and human islet cells proliferation. Mouse and human islets 
were cultured for 2 (A) or 4 (B-D) days on ECM-coated dishes in the absence (control) or presence of 
LDL (3.1 mM). A: BrdU positive mouse islet cells per islet after 2 days (n=3), control (absolute value): 
D C 
B A 
47 
3.87 positive cells/islet. B: BrdU positive mouse islet cells per islet after 4 days (n=9), control (absolute 
value): 3.09 positive cells/islet. C: BrdU positive mouse islet cells per islet after 4 days, with media 
changed and LDL freshly added every day (n=6), control (absolute value): 5.63 positive cells/islet. D: 
Ki-67 human islet cells per islet after 4 days (n=4), control (absolute value): 0.12 positive cells/islet. * 
represents p<0.05 by Student’s t test. 
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Figure 23: LDL decreases liraglutide induced mouse islet cells proliferation. Mouse islets were cultured 
for 4 days on ECM-coated dishes in the presence or absence (control) of liraglutide (Lira 1 mM) and in 
the absence (control) or presence of LDL (3.1 mM). A: BrdU positive mouse islet cells per islet after 4 
days (n=3), control (absolute value): 1.95 positive cells/islet. B: BrdU positive mouse islet cells per islet 
after 4 days with media changed and LDL freshly added every day (n=6), control (absolute value): 
5.64 positive cells/islet. Where * represents p<0.05 as tested by ANOVA followed by Bonferonni’s 
post-hoc test. 
 
 
A 
B 
48 
 
Figure 24: LDL decreases mouse -cell proliferation. Single mouse islet cells were cultured for 4 days 
on ECM-coated dishes in the absence (control) or presence of LDL (3.1 mM). A: BrdU positive mouse 
-cells after 4 days (n=6). Where * represents p<0.05 as tested by Student’s t test.  
 
 
To investigate whether LDL receptor was involved in the decrease of islet cells 
proliferation, islets isolated from LDL receptor -/- mice and control LDLR +/+ mice 
were incubated for 4 days with LDL and in the presence of liraglutide. The results 
obtained with LDLR -/- islets (fig 25B+D) were similar to those obtained with LDLR 
+/+ islets (fig 25A+C), where LDL decreased both basal and liraglutide induced 
proliferation, thus indicating that LDL receptor mediated LDL uptake was not involved 
in the anti-proliferative effect of LDL. 
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Figure 25: LDL decreased islet cells proliferation is independent of functional LDL receptor. Mouse 
islets from LDLR +/+ (A, C) or LDLR -/- (B, D) mince were cultured for 4 days on ECM-coated dishes 
in the presence or absence (control) of liraglutide (Lira 1 mM) and in the absence (control) or presence 
of LDL (3.1 mM). A: BrdU positive mouse islet cells per islet (n=3), control (absolute value): 1.06 
positive cells/islet. B: BrdU positive mouse islet cells per islet (n=3), control (absolute value): 2.33 
positive cells/islet. C: BrdU positive mouse islet cells per islet (n=3), control (absolute value): 1.06 
positive cells/islet. D: BrdU positive mouse islet cells per islet (n=3), control (absolute value) 2.33 
positive cells/islet. Where * represents p<0.05 as tested by ANOVA followed by Bonferonni’s post-hoc 
test (C, D) or Student’s t test (A, B).  
 
 
5.2.4 LDL and islet cells apoptosis 
Apoptosis of mouse and human islet cells was examined after 4 days incubation of 
the islets in the presence of LDL. LDL did not affect mouse or human islet cells 
apoptosis (fig 26A+B). 
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Figure 26: LDL does not affect islet cells apoptosis. Mouse (A) and human (B) islets were cultured for 
4 days on ECM-coated dishes in the absence (control) or presence of LDL (3.1 mM). A: TUNEL 
positive mouse islet cells per islet (n=3), control (absolute value): 0.68 positive cells/islet. B: TUNEL 
positive human islet cells per islet (n=3), control (absolute value): 0.34 positive cells/islet. 
C D 
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6 DISCUSSION 
 
Patients with type 2 diabetes typically display, along with hyperglycaemia, elevated 
circulating levels of free fatty acids and triglycerides and small dense LDL particles as 
well as low plasma levels of HDL cholesterol [121]. Even more so, low HDL 
cholesterol, hypertriglyceridemia and small dense LDL often precede the 
manifestation of diabetes mellitus type 2 and epidemiological studies unravelled low 
HDL cholesterol as an independent risk factor for developing type 2 diabetes [125]. In 
the past this association was explained as an innocent bystander effect of insulin 
resistance in the pre-diabetic state which interferes with several steps in HDL 
metabolism and thereby decreases HDL cholesterol either directly or by increasing 
free fatty acid levels. Most recent preliminary data in rodent -cells have indicated a 
role for lipoproteins in the regulation of islet cell survival and insulin synthesis 
suggesting a causal or modulatory role of lipoproteins in the precipitation of diabetes 
mellitus type 2 [73, 128]. The present thesis has examined the role of HDL and LDL 
on mouse and human pancreatic -cell apoptosis, proliferation and secretory 
function. The putative protective role of HDL on islet cells in the context of type 2 
diabetes has been investigated. Finally, with this work we have tried to uncover the 
mechanisms of action of HDL and LDL on islet cells. 
 
6.1 Role of HDL on -cell function, proliferation and apoptosis 
 
Plasma concentrations of lipoproteins are tightly controlled and are routinely 
evaluated in patients with diabetes. Concentrations of HDL > 1 mM and of LDL < 3.1 
mM are considered within the normal range. Diabetic patients have often a 
dyslipidemia characterized by reduced plasma concentration of HDL. Total LDL 
plasma concentration is not changed in diabetic patients, however the sub-
composition of LDL particles is changed, with increasing amount of small dense LDL 
that are more prone to modifications such as glycosylation or oxidation [120, 121, 
124]. The concentrations used to treat the human and mouse islets in the present 
study are within these ranges. However, the precise concentration of lipoproteins 
around the islets is not known. Nevertheless, since the islets are highly vascularized 
51 
and islet endothelium fenestrated, we assumed that the lipoprotein concentration in 
the plasma around the islets is similar to the one in the circulation. 
HDL has long been recognized as having a protective role on the arterial cell wall 
[132]. For example and in addition to its classical role in reverse cholesterol transport, 
HDL and its protein and lipid components exert anti-apoptotic and anti-inflammatory 
effects on endothelial and smooth muscle cells [67, 133]. This protective role of HDL 
has also been studied in murine islet cells and in the TC3 -cell line, where HDL 
had a protective effect on apoptosis induced by either a cocktail of cytokines, 
starvation or elevated LDL [73].  
In the present work, we found that HDL decreases basal islet cells apoptosis without 
influencing the function or the proliferation of these cells. Moreover, HDL protected 
islet cells from glucose and IL-1 induced apoptosis. These protective effects were 
specific for -cells as indicated by our immunological colocalization experiments. 
Furthermore, we showed that HDL influences human islet cells survival, suggesting 
relevance for human disease. The protective effects exerted by HDL on islet -cells 
are an interesting finding suggesting an important role for this particle in the survival 
of these cells and particularly in the context of type 2 diabetes. However, it stills 
remains to be determined if HDL directly acts on -cells or if the protective effect is 
mediated by another intermediary cell type, for example macrophages which were 
found to accumulate in pre-diabetic islets and to secrete potentially -cell-toxic 
cytokines [51]. HDL in turn is known to strongly influencing macrophage activation 
including inhibiting cytokine secretion. 
In an attempt to uncover the pathway by which HDL affects islet cells survival, HDL 
was separated into its protein and lipid moieties and both were investigated 
separately for their putative anti-apoptotic activity. The protein moiety of HDL 
displayed a trend to protect islet cells against IL-1 and glucose induced apoptosis. 
Moreover, the protective effect of purified ApoA1 against IL-1 induced apoptosis 
was statistically significant. Interestingly ApoA1 was previously found to exert similar 
anti-inflammatory effects also on endothelial cells [90]. 
Interestingly the lipid moiety of HDL protected islet cells from IL-1 induced 
apoptosis. Based on previous studies, which identified S1P as an inhibitor of 
apoptosis in endothelial cells and -cells from apoptosis [81, 103, 105], we also 
tested the anti-apoptotic effect of S1P. However, at a concentration of 100 nM S1P 
52 
only showed a statistically not significant trend to protect mouse islet cells from IL-1 
induced apoptosis. The discrepancy might be explained by the 10 to 1000 times 
lower S1P concentrations used here. 
In order to uncover the signaling pathways by which HDL supports -cell survival, we 
investigated the effects of HDL on signals which are known to mediate the apoptotic 
effects of IL-1, namely induced iNOS and Fas expression [134]. We observed that 
HDL decreases Fas mRNA expression and increases FLIP mRNA expression. Prior 
to the Fas and FLIP regulation which appeared after 4 days, HDL first down 
regulated iNOS mRNA expression. In -cells, up regulation of iNOS increases NO 
production. In turn, it is well established that NO, in -cells, regulates a set of genes 
that are involved in apoptosis and specifically Fas [49]. Our results indicate that HDL 
interferes with the upregulation of iNOS and Fas mRNA expression by IL-1. The 
expression of other genes involved in apoptosis, such as Bcl2 or SOCS3, was not 
influenced by HDL. MAP kinases, which are downstream effectors of IL-1 signaling, 
are known to regulate iNOS expression [47]. HDL decreased p38 phosphorylation 
induced by IL-1while HDL did not have any effect on JNK and ERK 
phosphorylation. 
Of note, in endothelial cells HDL also interferes with apoptotic signals by altering NO 
production. However in this case, HDL induces the phosphorylation of endothelial 
nitric oxide synthase (eNOS) and thereby increases NO production which is anti-
apoptotic in endothelial cells. [135]. Both S1P receptors and the HDL receptor SRB1 
have been shown to mediate the anti-apoptotic effects of HDL in endothelial cells 
[75]. While the role of S1P must be further investigated, we tend to exclude the 
involvement of SRB1 in HDL islet cells protection against IL-1 by finding the 
protective effects of HDL on IL-1 induced -cell apoptosis also in islets of SRB1 -/- 
mice. However, the results obtained in islets of SRB1 -/- mice must be interpreted 
with caution since the apoptosis induced by IL-1 in these islets is milder (1.5 x) 
compared to the apoptosis induced by IL-1 in islets from wild type mice (2 x). 
Overall we hypothesize (fig 28) that HDL influences positively -cell survival by down 
regulating iNOS and Fas mRNA expression. In parallel, HDL increases FLIP which 
may offer an additional protective effect. Upstream from iNOS regulation, other 
intracellular signaling proteins are probably regulated by HDL. In fact, HDL seems to 
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influence p38 phosphorylation and so decreasing the proapoptotic effect of IL-1. 
ApoA1 protects islet cells from IL-1 induced apoptosis, similarly to HDL. 
 
 
 
Figure 27: IL-1, by inducing iNOS and Fas expression induces -cell apoptosis. HDL, probably via its 
protein part, and specifically ApoA1, decreases Fas and iNOS, and increases FLIP mRNA expression 
thus resulting in a decrease in apoptosis. Moreover, HDL counteracts the pro-apoptotic effect of IL-1 
on -cells, independently of SRB1. In red: IL-1 effects on -cells that result in apoptosis. In green: 
HDL effects on -cells that increas cell survival 
 
 
6.2 Role of LDL on -cell function, proliferation and apoptosis 
 
Consistent with previously published results, we observed LDL receptor expression in 
human and mouse islets, and on Min6 cells [73, 131]. However, no LDL receptor 
transcripts could be detected in purified human -cells. The presence of LDL receptor 
in human -cells has never been directly investigated. Human -cells were shown to 
bind and internalize LDL particles [129, 131]. In other cell type, the major entrance 
door for LDL to the cells is the LDL receptor. However, it was never directly 
investigated if the LDL receptor is responsible for binding and uptake of the LDL 
particles observed in human -cells.  
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In this study we found that LDL decreases glucose-stimulated insulin secretion in 
mouse and human islets. The LDL receptor appears to play a central role in this 
functional impairment, since glucose-stimulated insulin secretion in islets obtained 
from the LDL receptor -/- mice was not influenced by the presence of LDL. We further 
hypothesize that LDL only affects the secretory machinery and not the production of 
insulin since no difference was observed in total insulin content or in insulin mRNA 
level of LDL treated and LDL untreated islets of either wild type mice or LDL receptor 
-/- mice. Since the LDL receptor acts as an endocytic receptor we propose that the 
impairment of glucose-stimulated insulin secretion by LDL is mediated by a 
component of LDL which is internalized by the LDL receptor pathway. Most likely this 
component is cholesterol because impaired cholesterol homeostasis is known to 
contribute to islet dysfunction. The impairment of insulin secretion that follows the 
accumulation of cholesterol into the -cells is a consequence of a defect in the 
secretory machinery and not of a defect in the insulin production [128]. With this 
work, we show that LDL, probably by causing cholesterol accumulation in the islet 
cells, impairs glucose-stimulated insulin secretion in -cells without influencing the 
insulin production. 
In parallel to the impairment of the secretory function of -cells, LDL also decreased 
the basal proliferation of mouse and human islet cells. However, in contrast to the 
effect on insulin secretion, this anti proliferative effect appears to be independent of 
LDL uptake by the LDL receptor, since islets from LDL receptor -/- mice were found 
as sensitive as wild type islets to the decrease in proliferation induced by LDL. This 
implicates that LDL effects on proliferation are probably independent of intracellular 
cholesterol accumulation, since the LDL receptor is the major entrance door for 
cholesterol. This anti-proliferative effect of LDL on -cells contrasts with previously 
published studies where LDL rather induced proliferation of smooth muscle cells 
[136], suggesting that the effects of LDL on the cell cycle is dependent on the cell 
type. A possible mediator of the anti-proliferative effect of LDL on -cells could be 
apoER2, which is expressed on -cells and which contributes to LDL signaling on 
platelets [73, 137]. However, other members of the LDL receptor family should not be 
neglected when investigating the pathway mediating the decrease in -cells 
proliferation induced by LDL. Finally, the decrease in proliferation could be reversed 
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by treating the cells in parallel with liraglutide, a GLP-1 analogue known to increase 
proliferation. 
The effects of LDL on islet cells survival are not clear. One study observed that 
elevated LDL induces apoptosis of islet cells and a murine -cell line [73]. However, 
Abderrahmani and collegues could not reproduce these effects using lower LDL 
concentrations, and they observed that LDL induces apoptosis only when it is 
oxidized and not in its native form [118]. In the present work, mouse and human islet 
cells survival was not influenced by the presence of low concentrations of LDL, 
suggesting that LDL probably increases apoptosis of the islet cells only at elevated 
concentrations or when it is modified by oxidation. 
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7 CONCLUSION AND FUTURE DIRECTIONS 
 
The present thesis was undertaken to elucidate the role of HDL and LDL on mouse 
and human pancreatic islet -cells secretory function, proliferation and apoptosis. 
The present work proposes that HDL protects basal islet cells apoptosis in addition to 
protecting the cells from glucose and IL-1 induced apoptosis. This work furthermore 
suggests that plasma concentrations of LDL should be tightly regulated since 
prolonged exposure to LDL impairs -cell insulin secretion and decreases islet cell 
proliferation. These deleterious effects can be partially prevented by the GLP-1 
analogue liraglutide. It is hoped that this thesis has provided some useful insights into 
the possible importance of well controlled LDL and HDL plasma concentrations to 
prevent the progressive decline in -cell mass responsible for the onset and 
progression of type 2 diabetes. Furthermore it is hoped that this knowledge will 
contribute to understand why low HDL concentration is a risk factor for developing 
type 2 diabetes.  
 
The main conclusions from this thesis are: 
HDL decreases basal mouse and human islet cells apoptosis. 
HDL protects -cells from IL-1 and glucose induced apoptosis, probably 
independently of SRB1. 
ApoA1 mimic the protective effect of HDL. 
The anti-apoptotic effects of HDL may be mediated via decreased iNOS and 
Fas, and increased FLIP expression. 
LDL impairs glucose-stimulated insulin secretion, dependent on functional LDL 
receptor. 
LDL decreases basal proliferation in mouse and human islets, an effect that is 
partly prevented by liraglutide. 
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8 MATERIEL AND METHOD 
 
8.1 Reagents 
 
Recombinant mouse and human IL-1 were obtained from R&D (R&D systems, 
Minneapolis, USA). Sphingosine-1-phosphate was obtained from Avanti (Avanti polar 
lipids, Alabaster, USA) and reconstituted in methanol. Human isolated ApoA1 was 
purchased from Calbiochem (Calbiochem, Gibbstown, USA). 
 
8.2 Cells 
 
8.2.1 Mouse islets isolation 
Mouse islets were isolated from C57BL/6J mice, LDL receptor -/- mice (Jackson 
Laboratory, USA), and SR-B1 -/- mice (kindly provided by G.Georgopoulos, Athens, 
Greece). The islets were isolated by collagenase digestion (Worthington Biochemical 
Corporation, Lakewood, USA) of the pancreas and separated from the exocrine 
tissue by density gradient (Histopaque-1119, Sigma-Aldrich, USA). Islets were further 
handpicked prior to plating for higher purity. 
 
8.2.2 Mouse islets culture 
Mouse islets were cultured in RPMI-1640 medium containing 11 mmol/l glucose, 40 
g/ml gentamycin, 100 units/ml penicillin, 100 g/ml streptomycin, 1% glutamax and 
10% FCS (Invitrogen, Basel, Switzerland). Islets were cultured on ECM-coated plates 
derived from bovine corneal endothelial cells (Novamed, Jerusalem, Israel). The 
islets were cultured in islet media for 48h to adhere to the ECM-coated plate and to 
spread prior to the initiation of the experiments. Islets were treated with 22 mmol/l or 
33 mmol/l glucose, recombinant mouse IL-1 (R&D, Minneapolis, USA), human 
lipoproteins, apolipoprotein A-1 (Calbiochem, San Diego, USA) or sphingosine-1-
phosphate. 
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8.2.3 Human islets culture 
Human islets were isolated from pancreta of organ donors at the University of 
Geneva Medical Centre (Geneva, Switzerland) and at the INSERM EIT-M 0106 in 
Lille (Lille, France). Human islets were cultured in CMRL-1066 medium containing 5 
mmol/l glucose, 100 units/ml penicillin, 100 g/ml streptomycin, 1% glutamax and 
10% FCS (Invitrogen, Basel, Switzerland). Islets were cultured on ECM-coated plates 
derived from bovine corneal endothelial cells (Novamed, Jerusalem, Israel). The 
islets were cultured in islet media for 48h to adhere to the ECM-coated plate and to 
spread prior to the initiation of the experiments. Islets were treated with 33 mmol/l 
glucose, recombinant human IL-1 (R&D, Minneapolis, USA) or human lipoproteins. 
 
8.2.4 Mouse single islet cells culture 
To obtain single islet cells, mouse islets freshly isolated were washed twice in Mg2+ 
and Ca2+ -free phosphate-buffered saline (PBS: 80g NaCl, 2g KCl, 11.5 g Na2HPO4 
2H2O, 2.5 g KH2PO4 in 10 litre H2O) + 0.5 mM EDTA. Thereafter, islets were 
incubated for 6 minutes at 37°C in 600 l trypsin-EDTA (Invitrogen, Basel, 
Switzerland) and 900 l Mg2+ and Ca2+ -free PBS + 0.5 mM EDTA. To ensure single 
cells, the islets were mechanically dispersed by pipetting and culture media was 
added to stop the trypsinisation. Cells were centrifuged (1000 rpm for 3 minutes), 
resuspended in culture media, and plated on ECM-coated plates for culture. 
 
8.2.5 Cell lines culture 
The murine insulinoma cell line Min6 was cultured in regular cell culture dishes in 
DMEM medium containing 25 mM glucose and glutamine completed with 40 g/ml 
gentamycin, 100 units/ml penicillin, 100 g/ml streptomycin, 15% FCS and 0.1% -
mercaptoethanol (Invitrogen, Basel, Switzerland) 
The rat insulinoma cell line INS1E was cultured in regular culture dishes in RPMI-
1640 medium containing 11 mmol/l glucose, 40 g/ml gentamycin, 100 units/ml 
penicillin, 100 g/ml streptomycin, 1% glutamax, 10 mM Na pyruvate, 0.1% 
glutamax, 10 mM -mercaptoethanol and 10% FCS (Invitrogen, Basel, Switzerland). 
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8.3 Lipoproteins 
 
8.3.1 Isolation of human lipoproteins 
Blood was collected from healthy donors. Plasma low density lipoprotein (LDL) and 
high density lipoprotein (HDL) fractions were isolated by sequential ultracentrifugation 
(LDL: 1.006 < LDL density < 1.063; HDL: 1.063 < HDL density < 1.21), dialyzed 
against LDL-buffer (NaCl 1.5 M, EDTA 3 mM, pH 7.4) and finally filter sterilized using 
a 0.22 m microfilter. Cholesterol concentration was measured using an enzymatic 
test. The purity of the lipoprotein preparation was verified by apolipoprotein 
composition analysis in a 10% sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) to exclude contaminations with LDL or albumin in the 
HDL fraction and to exclude contamination with HDL or albumin in the LDL fraction. 
Lipid-free HDL protein moiety was further extracted from HDL as described 
previously [138].  
 
8.3.2 Preparation of reconstituted HDL 
Discoidal reconstituted HDL (rHDL) was produced out of a complex containing 1-
palmitoyl-2-oleyl-L-palmitoyl-sn-glycero-3-phosphatidylcholine (POPC) (Fluka), lipid –
free HDL protein moiety and sodium cholate (NaCholate) in a molar ratio of 
100/1/100. In brief 2.71 mg of POPC was dissolved in CHCl3, added to a conical 
glass tube and dried under nitrogen. Thereafter, POPC was dissolved in 0.4 ml Tris 
saline (0.01 M Tris, 0.15 M NaCl, 0.005 mM EDTA), pH8. The mixture was vortexed 
thoroughly and stored on ice for 1 hour. 100 l NaCholate (from 157 mg/ml stock 
solution) was added and the mixture was then vortexed every 10 min for 75 min until 
completely clear. After clearing, 1 mg of lipid-free HDL protein moiety in Tris saline 
was added and the mixture was then incubated for 1 hour on ice. Finally the 
reconstituted HDL was extensively dialysed at 4°C in Tris saline. 
 
8.3.3 Extraction of the HDL lipid fraction 
Human HDL was further processed to extract its lipid fraction. HDL was diluted in 
H2O to obtain 1 ml of solution and the pH was adjusted to 3.0 with sulphuric acid 
(H2SO4). A biphasic (aqueous/organic) mixture was then formed by the addition of 1 
ml of acetonitril (C3H3N) to the diluted acidic HDL. 0.5 g NaCl was also added. The 
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mixture was centrifuged at 800 g for 5 min at room temperature. The upper organic 
phase, containing the HDL lipid fraction, was transferred in a new vial and 
lyophylised. The lipid fraction was resuspend in ethanol and rapidly injected in PBS 
containing 1% fatty acid free BSA while vortexing. 
 
8.4 RNA isolation and RT-PCR 
 
8.4.1 Total RNA isolation 
Total RNA was isolated from 100 mouse or human islets plated on ECM-coated 
culture dishes with a total RNA extraction kit (NucleoSpin RNAII, Marcherey Nagel, 
Düren, Germany). The cells were harvested by scraping them off the plate in the RA1 
buffer provided with the RNA extraction kit. The lysed cells were transferred to the 
purification column and RNA was further extracted according to the manufacturer’s 
instruction. 
 
8.4.2 Reverse transcription 
First strand cDNA synthesis was performed using 1 l (200U) SuperScriptTM II RT 
(Invitrogen, Basel, Switzerland). Typically 3 l dTT,  2 l mixed dNTPs (10 mM each),  
12 l 5x First-Strand Buffer, 1 l random hexamers, 1 l Supercript and 0.5 l RNase 
inhibitor were mixed with 40 l RNA and incubated at 37°C for 2 hours. The 
enzymatic reaction was stopped by incubating the samples at 70°C for 15 min. After 
a quick spin down, the cDNA samples were stored at -20°C. 
 
8.4.3 Polymerase chain reaction 
The conventional polymerase chain reaction (PCR) was performed with cDNA 
samples obtained from the reverse transcription. 2 l cDNA were mixed with 25 l 
TaqMan PCR Master Mix (Qiagen, Germantown, USA), 2 l forward primer (10 M), 
2 l reverse primer (10 M) and 19 l H2O to obtain a final volume of 50 l. Specific 
primer sequences and annealing temperatures are listed in tables 1 and 2. Typical 
cycling parameters were: 1 cycle 94°C for 1 min, 25 to 45 cycles 92°C 1 min + 52-
56°C 1 min + 72°C 1 min and finally 1 cycle 72°C 7 min, performed with the 
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TGradient PCR machine (Biometra, Göttingen, Germany). The PCR products were 
analysed on a 2% polyacrylamide gel containing 0.006% ethidium bromide. 
 
8.4.4 Semi-quantitative polymerase chain reaction 
The TaqMan technology (Applied Biosystems, USA) was used as the semi-
quantitative PCR method. The cDNA samples, obtained from the reverse 
transcription, were diluted 1/12 in H2O prior to their loading on a 96-well reaction 
plate (MicroAmp, Applied Biosystems, USA). The specific primers containing the 
fluorescent probe were diluted 1/10 in Universal PCR Master Mix (TaqMan, Applied 
Biosystems, USA) and then added to the samples on the reaction plate. The specific 
TaqMan primers are listed in table 3. The detection of the amplification was 
performed with the 7500 Fast Real-Time PCR System (Applied Biosystems, USA). 
 
8.5 Western Blot 
 
8.5.1 Protein isolation and protein concentration measurement 
The proteins were extracted from approximately 200 mouse islets plated on ECM-
coated dishes. Following a washing step in 1 ml PBS, the islets were scrapped of the 
culture dish and put in a tube containing 1 ml PBS. After a centrifugation at 2000 rpm 
for 5 min at 4 °C, the supernatant was discarded and the pellet was respuspended in 
100 l of lysis buffer containing: 20 mM Tris (pH 7.5), 150 mM NaCl, 1% Triton X-
100, 10% Glycerol, 10 l Protease inhibitor cocktail (Roche, Basel, Switzerland), 1 
mM Na3VO4, 1 mM NaF, 0.5 mM PMSF and 1 mM EDTA (pH 8) and then incubated 
for 15 min on ice. The lysate was sonicated and centrifuged at 13000 rpm for 10 min 
at 4°C. The supernatant containing the proteins was stored at -20°C. The 
concentration of the protein was measured with the conventional bicinchoninic acid 
(BCA) protein assay kit (Pierce, Rockford, USA). 
 
8.5.2 Western Blotting 
Equivalent amount of protein lysate (20-50 g) were mixed with SDS sample buffer 
and denaturated at 70°C for 10 min and subjected to a 10% sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE). Proteins were electrically 
transferred to nitrocellulose filter membranes. Blocking of non-specific protein binding 
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was done by incubating filter membrane in blocking buffer (1xTBS 3.03 g Tris-HCl, 
8.7 g NaCl in 1 l H2O (pH 7.6), 0.1% Tween-20 and 5% non-fat dry milk) for 1 hour. 
After washing in TBS-T (1 x TBS (pH 7.6), and 0.1% Tween-20), filters were 
incubated at 4°C overnight with the specific primary antibodies. Subsequently, filter 
membranes were washed in TBS-T and incubated for 1 hour with horseradish 
peroxidise-conjugated secondary antibodies. Immune complexes were detected by 
chemoluminescence using LumiGLO (Cell singaling technology, Danvers, USA) and 
light emission was captured on X-ray film. 
 
8.6 Detection of Apoptosis 
 
8.6.1 Fluorescence 
Mouse and human islets on ECM-coated dishes were fixed with 4% 
paraformaldehyde for 30 min at room temperature. The cells were permeabilised with 
Triton-X for 4 min prior to their staining. The free 3’-OH strand breaks resulting from 
DNA degradation were detected by the terminal deoxynucleotidyl-transferase-
mediated dUTP nick-end labelling (TUNEL) technique according to the 
manufacturer’s instructions (In Situ Cell Death Detection Kit, Roche, Basel, 
Switzerland). Islets were co-stained for insulin with a guinea pig anti-insulin antibody 
(DakoCyomation, Glostrup, Denmark). The number of apoptotic cell was determined 
by a careful counting with a fluorescent microscope (Axioplan 2, Zeiss, Germany).  
 
8.6.2 Confocal 
Mouse islets were co-stained for apoptosis (TUNEL, as described above), insulin and 
their nucleus (4’,6-diamidino-2-phenylindole, DAPI). Multiple labelling 
immunofluorescence images of mouse islets were captured using a scanning 
confocal head coupled to an upright microscope (TCS SP2, Leica, Wetzlar, 
Germany) with UV light and an Ar-Kr laser utilizing 358 nm, 488 nm and 647 nm 
excitation and a 63x/1.40 oil PlanApo objective lens. For each islet a series of eight 
pictures, corresponding to eight different z plans, was acquired with Leica software 
(Leica, Wetzlar, Germany) and merged. The series allowed the determination of the 
number of apoptotic -cell and apoptotic non -cell for each islet. 
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8.6.3 Cell line 
The apoptosis in the different cell lines was ascertained using Cell Death Detection 
ELISA (Roche, Basel, Switzerland) following manufacturer’s instructions. Because 
the lysis buffer contained in the ELISA assay did not allow the determination of the 
protein concentration with any method and though the cell number plated in each 
well was consistent, 2 identical 24-well plates for each experiment were treated and 
analysed in parallel. One was used for apoptosis determination and the other was 
used for protein concentration measurement. The supernatant was analysed with 
Bicinchoninic acid (BCA) Protein Assay kit (Pierce, Rockford, USA) to determine the 
protein concentration. 
 
8.7 Detection of Proliferation 
 
8.7.1 Ki-67 staining 
For human islet cells proliferation studies, a monoclonal antibody against the human 
Ki-67 antigen (Zymed laboratories, San Fransisco, USA) was used. Islets were co-
stained for insulin with a guinea pig anti-insulin antibody (DakoCyomation, Glostrup, 
Denmark). The number of proliferative cell per islet was determined by a careful 
counting with a fluorescent microscope (Axioplan 2, Zeiss, Germany).  
 
8.7.2 BrdU staining 
For mouse islet cells proliferation studies, BrdU was added to the mouse islets at the 
start of the treatment. The incorporated BrdU was detected with an anti-Brdu 
antibody (Roche, Basel, Switzerland). Islets were co-stained for insulin with a guinea 
pig anti-insulin antibody (DakoCyomation, Glostrup, Denmark). The number of 
proliferative cell per islet was determined by a careful counting with a fluorescent 
microscope (Axioplan 2, Zeiss, Germany).  
 
8.8 Functional test 
 
8.8.1 Glucose-stimulated insulin secretion 
For acute insulin release in response to glucose, islets were washed and incubated in 
Krebs-Ringer buffer containing 2.8 mmol/l glucose and 0.5% BSA for 1h (= basal 
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secretion). The islets were then incubated in Krebs-Ringer buffer containing 16.7 
mmol/l glucose and 0.5% BSA for 1h (= stimulated secretion). The total insulin 
content was obtained by measuring the insulin concentration in the supernatant of 
the islets incubated for 2 hours at room temperature with acid ethanol. Secreted 
insulin was assayed by radioimmunoassay (CIS Biointernational, Gif-sur-Yvette, 
France).  
 
8.9 Statistical analysis 
 
Data are expressed as means ± SEM, with the number of individual experiments 
presented in the figure legends. All data were tested for normality and analysed with 
PRISM (GraphPad, San Diego, USA). Significance was tested using the Student’s t 
test and ANOVA with Bonferonni’s post hoc test for multiple comparison analysis. 
Significance was set as p<0.05. All experiments were done at least in triplicates and 
considered as n=1. 
 
8.10 Tables 
 
Gene Direction Primer Sequence (5'-3') PCR Annealing Temp (°C)
CD 36 Forward TCGGAACTGTGGGCTCATTG 55
Reverse CCTCGGGGTCCTGAGTTATATTTTC
SRBI Forward GGAATCCCCATGAACTG 52
Reverse AGCCCTTTTTTACTACCACTCC
ABCA1 Forward TGCCCTATGTGCTGTGCGTAG 55
Reverse GGTGAGATTGAAGCCGTCCTC
GAPDH Forward CGACCCCTTCATTGAC 55
Reverse TCCACGACATACTCAGCAC  
 
 
Gene Direction Primer Sequence (5'-3') PCR Annealing Temp (°C)
CD36 Forward ATATGGTGTGCTAGACAT 55
Reverse CATCACCACCACCAACAC
SRBI Forward GGAATCCCCATGAACTG 55
Reverse CAGGCAAGCGAATGGC
ABCA1 Forward GTCATTATCATCTTCATCTGCTTCC 55
Reverse CCTCACATCTTCATCTTCATCATTC  
 
 
Table 1: Primers sequences for target gene amplification in mouse with conventional PCR. 
Table 2: Primers sequences for target gene amplification in human with conventional PCR. 
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Gene AssayID Assay Location
Socs3 Mm01249143_g1 289
Bcl2 Mm00477631_m1 1978
Nos2 Mm01309902 1168
Fas Mm00433237 76
Flip Mm01255580 1780  
 
 
 
 
Table 3: Primer references for target gene amplification in mouse with TaqMan real-time PCR 
(Applied Biosystems) 
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